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AIM 
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AIM 
 
To study the cardiovascular consequences in a prospective cohort of children aged 1-18 years 
with Chronic Kidney Disease(CKD) with Glomerular Filtration Rate (GFR) < 60 ml/min/1.73 
m^2.   
  
 
OBJECTIVES 
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OBJECTIVES 
 
Primary Objectives: 
1. To study the prevalence of Hypertension both manifest (clinic BP Readings) and masked 
(Ambulatory BP monitoring).  
2. To study prevalence of Left Ventricular Dysfunction in children with CKD using 
Echocardiogram as a tool. 
 
Secondary Objectives: 
1. To study differences in BMI in children on different modalities of treatment for CKD. 
2. To compare the cardiovascular risks between children with CKD not requiring dialysis and 
those on dialysis. 
3. To assess the correlation between the calcium-phosphorus product and correlate with risk for 
vascular calcification. 
  
 
INTRODUCTION 
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INTRODUCTION 
 
Chronic Kidney Disease is an emerging problem worldwide. With increasing awareness about 
kidney diseases and antenatal ultrasound screening we are detecting more children with  
congenital anomalies of the kidney and renal tract (CAKUT).  In India the prevalence of CKD 
is estimated to range form 0.79-1.4% in the adult population 
1
 . The prevalence of CKD 
amongst Indian children is not known. 
The National Kidney Foundation, Kidney Disease Outcome Quality Initiative workgroup has a 
classification for patients with CKD who are older than two years 
2
: 
Stage 1 disease — Normal GFR (≥90 mL/min per 1.73 m^2) 
Stage 2 disease — GFR between 60 and 89 mL/min per 1.73 m^2 
Stage 3 disease — GFR between 30 and 59 mL/min per 1.73 m^2 
Stage 4 disease — GFR between 15 and 29 mL/min per 1.73 m^2 
Stage 5 disease — GFR of less than 15 mL/min per 1.73 m^2 or end-stage renal disease (ESRD) 
 
As per this definition children with > Stage 3 CKD are categorized to have Chronic Renal Failure 
(GFR <60 ml/min/1.73m^2). These children develop various morbidities associated with renal 
failure and need close monitoring of growth parameters. They have special dietary needs and 
require being on regular medications. Meticulous control of metabolic parameters and avoidance 
of nephro-toxic drugs can prevent progression to End Stage Renal Disease.  
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There are many treatment options available for children with chronic kidney disease.Renal  
replacement in the form of Dialysis or Renal Transplantation is possible and with this supportive  
care, children with ESRD can survive much longer and can lead near-normal lives. The early age  
of onset of disease in children with CKD and their increased longevity make them more  
susceptible to the long term complications of renal failure. 
Cardiovascular risks like Hypertension, LV Dysfunction and Atherosclerosis are rare amongst the 
general pediatric population (< 3%)
3
 but in children with CKD are a leading cause of mortality 
and morbidity 
45
. In adolescents with CKD the cardiovascular morbidity is 500-1000 times more 
than the general population 
6
.  
No studies have been undertaken so far to study the cardiovascular risk factors in Indian children 
with CKD. More studies and systemic reviews are required in this field to increase our 
knowledge and to institute preventive strategies to delay progression of renal disease. Identifying 
children with CKD who are at risk for cardiovascular disease early will help them live longer. 
Together with better medical management and Renal Replacement Therapy the morbidity and 
mortality may decrease further. This study was thus designed to determine the cardiovascular risk 
factors prevalent amongst children with CKD and to identify factors associated with poorer 
outcomes.  
  
 
LITERATURE 
REVIEW 
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LITERATURE REVIEW 
 
Chronic Kidney Disease (CKD) is a common problem worldwide and is rapidly increasing due to 
increasing awareness about kidney diseases and antenatal fetal ultrasound screening. In the USA 
the CDC has documented CKD in 16.85/1000 of the general population aged > 20 years in the 
year 1999-2004 which is a 15.9% increase when compared to the years 1988-1994 according to 
the National Health and Nutrition Examination Survey. In a study conducted by Soylemezoqlu et 
al in Turkey the prevalence of CKD amongst children aged 5-10 years was found to be 0.94 ( 95
th
 
% CI 0.63-1.35) 
7
. According to the US Renal Data System 2011 annual report the incidence of 
CKD has increased by 1.1% to 355.4 per million populations 
8
. In Serbia, amongst 336 children 
studied Peco Antic et al found the median annual incidence of CKD 2-5 stages was 14.3 per 
million age-related population (p.m.a.r.p), while those of CKD 2-4 or CKD 5 were 9.1 and 5.7 
p.m.a.r.p., respectively 
9
. In the Ital Kid study the mean incidence of CKD amongst Italian 
children was 12.1 per million age related population 
10
 with a point prevalence of 74.7 per million 
age related population. In India the prevalence of CKD is estimated to range form 0.79-1.4% in 
the general population 
1
 . The prevalence of CKD amongst Indian children is not known. 
  
The treatment of ESRD in Low and Medium Income countries (LMIC) is very difficult 
due to lack of financial support. In South East Asia, Renal Replacement Therapy costs 10 
times the annual per capita income and there is very low coverage of these expenses by 
health insurance 
11
. This high cost of treatment leads to less than 10% of people with 
ESRD receiving RRT in LMIC.  
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With the sharp rise in obesity and metabolic syndrome amongst Indian children and adolescents, 
they too are more susceptible to develop chronic kidney disease 
12,13
.  
Now there are many treatment options available for children with chronic kidney disease. 
Meticulous control of metabolic parameters and avoidance of nephro-toxic drugs can prevent 
progression to end stage renal disease. Renal replacement in the form of Dialysis or Renal 
Transplantation is possible and with this supportive care, children with ESRD can survive much 
longer and can lead near-normal lives. The early age of onset of disease in children with CKD 
and their increased life span make them more susceptible to the long term complications of renal 
failure.  
 
Definition: 
Chronic Kidney Disease was defined by the National Kidney Foundation in 2002:  
a. Kidney damage for >3 months, as confirmed by kidney biopsy or markers of kidney damage, 
with or without a decrease in glomerular filtration rate or  
b. GFR <60 mL /min/ 1.73 m^2 for >3 months, with or without kidney damage 
14
.  
The National Kidney Foundation, Kidney Disease Outcome Quality Initiative workgroup has a 
classification for patients with CKD who are older than two years 
2
: 
Stage 1 disease — Normal GFR (≥90 mL/min per 1.73 m^2) 
Stage 2 disease — GFR between 60 and 89 mL/min per 1.73 m^2 
Stage 3 disease — GFR between 30 and 59 mL/min per 1.73 m^2 
Stage 4 disease — GFR between 15 and 29 mL/min per 1.73 m^2 
Stage 5 disease — GFR of less than 15 mL/min per 1.73 m^2 or end-stage renal disease (ESRD) 
 
7 
 
 
 In children < 15 years of age, estimated GFR (eGFR) is calculated using Serum Creatinine 
values according to the Schwartz Formula. In older children (> 15 years) the Cockcroft-Gault 
formula is used to calculate eGFR.  
 
Estimated GFR by Schwartz formula is calculated by:  
GFR mL/min/1.73m^2 = k X Height (cm) 
                                         Serum Creatinine (mg/dl) 
                 where k is 0.33 for low-birthweight infants <1 yr old 
                 0.45 for term infants <1 yr old whose weight is appropriate for GA 
                 0.55 for children and adolescent girls 
                 0.70 for adolescent  
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ETIOLOGY OF CKD: 
The causes of CKD amongst children less than 5 years old are most commonly a result of 
congenital abnormalities such as renal hypoplasia, dysplasia, or obstructive uropathy. 
Other causes include congenital nephrotic syndrome, prune belly syndrome, cortical 
necrosis, focal segmental glomerulosclerosis, polycystic kidney disease, renal vein 
thrombosis, and hemolytic uremic syndrome. 
In children older than 5 years of age acquired diseases (glomerulonephritis including 
lupus nephritis) and inherited disorders (familial juvenile nephronophthisis, Alport 
syndrome) are more common. Metabolic disorders (cystinosis, hyperoxaluria) and 
inherited disorders (polycystic kidney disease) can also cause CKD.  
The NAPRTCS report showed that congenital causes, including congenital anomalies of 
the kidney and urinary tract (CAKUT) (48%) and hereditary nephropathies (10%) were 
the most common causes of CKD amongst children 
15
.  
In a study done by P Hari et al in AIIMS India the etiology of CKD amongst children was 
found to be 
16
: 
Cause Number Percentage 
Chronic Glomerulonephritis 84 27.5 
Reflux Nephropathy 51 16.7 
Obstructive Uropathy 97 31.8 
Neurogenic Bladder 14 4.5 
HUS 5 1.6 
Renal Dysplasia 15 4.9 
Hereditary Nephropathy 20 7.5 
9 
 
Miscellaneous Cortical Necrosis 2 0.6 
Unknown 17 5.7 
 
 
 
COMPLICATIONS OF CHRONIC KIDNEY DISEASE 
17
: 
Metabolic acidosis: Kidney is the major organ involved in acid base balance and the main organ 
that eliminates fixed acids (sulphuric, phosphoric acids) that are produced in the body due to 
metabolic activity. In renal failure, the inability to eliminate these fixed acids leads to metabolic 
acidosis. Metabolic acidosis is defined as serum bicarbonate < 20 mEq/L or need for bicarbonate 
supplementation 
18
.  The prevalence of metabolic acidosis increases with worsening renal failure. 
In stage 1 CKD 0.97% children were acidotic, whereas in stage 4 and 5 CKD the prevalence of 
acidosis was 54.55%.  
Growth failure: According to the North American Renal Trial and Collaborative Study 37 % of 
children with CKD and 47% of children on dialysis had significant short stature 
19
. The factors 
leading to short stature in CKD are non-hormonal factors such as anorexia leading to poor 
nutrition, electrolyte imbalance, anemia, metabolic acidosis and renal osteodystrophy as well as 
10 
 
hormonal factors such as growth hormone deficiency and resistance 
20
. Those with worsening 
stage of CKD are shorter. A Cochrane review showed that treatment with recombinant human 
growth hormone resulted in an increase in height velocity amongst children with CKD but the 
studies were not long enough to predict adult height 
21
 . In renal transplant recipients, there is 
some evidence that growth hormone therapy may be detrimental to graft function. 
 
Delayed Puberty: Delayed puberty occurs in children with CKD 
18
 and partly contributes to the 
short stature because of the absence of the pubertal growth spurt. 
  
Electrolyte Disturbances: Hyperkalemia can occur due to drugs, metabolic acidosis, and 
constipation and prolonged fasting. Hyponatremia is more common than hypernatremia. The 
main cause of hyponatremia is excessive free water intake 
22
.  
 
Metabolic Bone Disease: Metabolic bone disease is common in advanced stages of CKD in 
children. It is almost universal amongst children with stage 4 and 5 CKD, while only a minority ( 
6.28%) of children with CKD stage 1 have bone disease. Pathogenesis of metabolic bone disease 
in CKD is complex. The renal inability to excrete phosphate leads to hyperphosphatemia. This 
results in lowering of serum calcium levels and stimulates production of parathyroid hormone 
and this secondary hyperparathyroidism leads to bone resorption. Further there is a decrease in 
production of 1,25 di-hydroxy vitamin D in CKD because of poor tubular function & 
hyperphosphatemia. This in turn leads to mineralization defects (osteomalacia). The growing 
child has a greater need for vitamin D. The markedly reduced 1’25 (OH) D levels in CKD are 
11 
 
particularly harmful to the growing skeleton. Metabolic acidosis per se causes loss of calcium 
from bone and compounds matters.  
 
Hyperphosphatemia severe enough to warrant use of Phosphate binders, need for active Vitamin 
D metabolites or PTH levels >70 pg/ml (10 picomoles/L) are markers of bone disease. In renal 
tubular disease leading to CKD, phosphate wasting from tubular disease 
18
 is a major cause of 
bone disease.  
 
Proteinuria: The degree of proteinuria increases with the increasing stage of CKD, and this is 
independent of the cause of CKD 
23
.  
 
Anemia: Only 31.25% of Children with CKD stage 1 are anemic while upto 93.3% of those with 
stage 4 and 5 CKD have anemia. This is an added factor that impedes linear growth in children 
with CKD. 
 
Hypertension: 18% of children with CKD have overt hypertension as made out with clinic 
readings whereas an additional 38% have masked hypertension which can only be made out with 
ambulatory BP monitoring 
24
. Sodium and fluid retention, Left Ventricular dysfunction, 
atherosclerosis and arteriosclerosis all contribute to hypertension.  
 
Fluid Overload: Fluid overload is a common complication in CKD patients specially those 
undergoing dialysis 
25
. Fluid overload, hypertension and anemia contribute to LVH and indirectly 
to increased cardiovascular mortality.  
12 
 
Atherosclerosis: Normal children rarely ever have atherosclerosis. Early onset atherosclerosis is 
well studied amongst children with CKD 
26
.  
 
LVH: Children with CKD have LV Hypertrophy compared to age and sex matched controls. The 
degree of LV Hypertrophy correlates to the duration of CKD and the stage of CKD 
24
 
.  
Congestive Heart Failure: It is very difficult to differentiate fluid overload state form CCF 
amongst children on dialysis. Similarly it is equally difficult to differentiate salt and water 
retention due to inadequate dialysis from signs of CCF. Detection of hypotension during the 
course of dialysis plays in key role in determining which factor is predominant. Hypotension is a 
major cause of inadequate ultrafiltration during dialysis.  
 
CARDIOVASCULAR RISKS IN CHILDREN WITH CKD: 
Unlike adults, children are less likely to present with angina, myocardial infarction, or ECG 
abnormalities of Left Ventricular hypertrophy.  In view of these differences between adults and 
children in terms of cardiovascular problems, it is important to evaluate for latent risk factors for 
cardiovascular disease in children and treat them aggressively to reduce cardiovascular morbidity 
mortality.  
With renal replacement therapy, even though the lifespan of children with CKD has increased 
considerably, there is a greater susceptibility to cardiovascular morbidity due to the adverse  
effects of hypertension, fluid overload, left ventricular dysfunction and dsylipidemia.  
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The traditional risk factors for cardiovascular disease as defined by the Framingham study 
are:  
a. Older age 
b. Male sex 
c. Hypertension 
d. Higher LDL cholesterol 
e. Lower HDL cholesterol 
f. Diabetes 
g. Smoking 
h. Physical inactivity 
i. Menopause 
j. Family history of CVD 
k. LVH 
Many of the above are not pertinent to the pediatric population.  
As outlined by Wong et al novel non-traditional risk factors/ Uremia related risk factors for 
cardiovascular risks amongst children with CKD have also been described ( 5):  
a. Albuminuria 
b. Homocysteine 
c. Lipoprotein (a) and apolipoprotein(a) isoforms 
d. Lipoprotein remnants 
e. Anemia 
f. Abnormal calcium/phosphate metabolism 
g. Extracellular fluid volume overload 
14 
 
h. Electrolyte imbalance 
i. Oxidative stress 
j. Inflammation (C-reactive protein) 
k. Malnutrition 
l.  Thrombogenic factors 
m. Sleep disturbances 
n. Altered nitric oxide/endothelin balance 
o. Infection (Chlamydia pneumoniae) 
p. Peripheral Renin-Angiotensin-Aldosterone activity 
 
CARDIOVASCULAR MORTALITY: 
Cardiovascular disease is a leading cause of mortality and morbidity amongst children with CKD 
45
. Mortality due to cardiovascular causes is rare (less than 3%) amongst the general pediatric 
population 
3
. In adolescents with CKD the cardiovascular morbidity is 500-1000 times more than 
the general population 
6
.  
In a study done by the European Dialysis and Transplant Association Registry, 41% of deaths in 
children < 15 years with CKD were due to cardiovascular causes 
27
. Identical results were 
reported by the Dutch retrospective study in which cardiovascular causes accounted for 41% of 
deaths   
28
. The most common causes of cardiovascular mortality were: cerebro-vascular 
accidents, congestive cardiac failure, myocardial infarction and sudden cardiac death (cardiac 
arrest) respectively. Data from the Australian and New Zealand Renal Transplant Registry also 
showed mortality up to 30 times higher than the general population with 45% of the deaths 
caused by cardiovascular events 
29
.  However a lower cardiovascular mortality of 23% was 
15 
 
reported by the US Renal Data Systems (a retrospective analysis of the cause of death from 1990-
1996 in US children with ESRD) 
30
.   
 
 
Study Registry 
Author Number of  
children 
Recruited 
Mortality due to 
Cardiovascular 
Risks (%) 
Reference 
European Dialysis and 
Transplant Association 
Registry 
Multiple 5482 41 
31
 
Dutch Registry Groothoff et al 381 41 
32
 
Australian and New Zealand  
Renal Transplant Registry 
Mc Donald SP 
et al 
1634 45                          (30 
(30 times greater) 
29
 
US Renal Data Systems Parekh et al 1380 23 
33
 
 
According to Parekh et al in the US Renal Data System the most common cardiac causes of  
mortality amongst adults was coronary artery disease followed by congestive cardiac failure,  
whereas amongst children sudden cardiac death (cardiac arrest)  arrhythmias and  
cardiomyopathy respectively are the commonest causes of mortality 
33
.  
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PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE 
3
: 
Cardiac remodeling occurs which leads to left ventricular (LV) Hypertrophy. There are two main 
types of LVH: 
1. Concentric LVH occurs in condition of pressure over-load secondary to long standing 
hypertension.  
2. Eccentric LVH occurs in condition of volume overload due to sodium retention, anemia, A-V 
Shunts 
34
.  
Pressure hypertrophy causes a parallel pattern of sarcomere arrangement. This results in 
increased wall thickness and concentric LVH. 
Volume overload causes sarcomeres to be arranged in series with an increase in the longitudinal 
cell growth. The LV dilatation is disproportionate to the wall thickness leading to eccentric LVH.  
The flow chart given below summarizes the changes in the heart in CKD. 
17 
 
 
Atherosclerosis is the other major contributor to cardiovascular disease. It involves the formation 
of an atheromatous plaque in the intima of the artery. The plaque is formed by fat containing 
macrophages called foam cells. Patchy irregular dystrophic calcification of the plaque ensues 
once the plaque ruptures. This calcification is due to several factors such as metabolic acidosis, 
inflammation and mechanical shear stress, the Ca X P product which tends to be high due to 
elevated serum phosphate in CKD, and treatment of renal osteodystrophy with 1,25 dihydroxy 
Vitamin D and calcium citrate. There are other mechanisms involved in the process of 
18 
 
calcification. For example, the levels of serum Fetuin A, an effective inhibitor of calcium-
phosphorus complex formation is lowered in children with CKD.  
 
Measurements of the carotid intima-medial thickness or inducible myocardial ischemia detected 
by coronary stress test are reliable markers for the presence of atherosclerosis.  
The endothelial progenitor cells help in the repair of damaged intima and prevent plaque 
formation. However in children with CKD there is a reduction in the number of Endothelial 
Progenitor cells and this impairs the process of endothelial repair and thus contributes to 
atherosclerotic damage.  
 
Arteriosclerosis is increased arterial rigidity of the entire arterial tree. It involves both intimal and 
medial involvement. It increases the wall thickness and the length of the arteries in turn leading to 
an increase in systolic BP, arterial thickening and pulse pressure.  
 
HYPERTENSION:  
Hypertension: 
Up to 18 % of children with CKD have confirmed hypertension, whereas an additional 38% can 
have masked hypertension 
35
. The cause of hypertension is multi-factorial: fluid overload, Left 
Ventricular dysfunction, atherosclerosis and arteriosclerosis 
4
. Hypertension is a very important 
risk factor in progression of CVD in CKD children since it is amenable to early detection and 
treatment.  
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White Coat HT: 
White Coat HT is more pronounced amongst children than in adults. Children are more likely to 
have high BP readings in a Clinic setting, with normal BP values outside the clinic. To detect true 
HT amongst children, clinic BP readings are not adequate.  This can lead to over diagnosis of HT 
and undue treatment with Anti HT medications.  
 
Masked HT: 
Masked hypertension is defined as Clinic BP less than 95
th
 centile for age and sex, but Mean SBP 
by ABPM greater than 95
th
 centile and SBP Load greater than 25 %. Masked HT cannot be 
detected by clinic BP readings alone and requires ABPM for detection.  
 
Ambulatory BP Monitoring (ABPM): 
ABPM helps to circumvent the problem of White coat HT. It allows BP monitoring while the 
child is in his/her own surroundings and doing their normal day to day activities. Most 
importantly it measures night time BP levels which are important predictors of cardiovascular 
outcomes.  
It is considered the gold standard in detecting hypertension amongst CKD patients.  Ambulatory 
BP Monitoring has been found to be more sensitive in detecting latent Hypertension than Clinic 
BP readings 
36
. 
In the ESCAPE trial ABPM was found to co-relate closely with Home BP Monitoring when 
compared to Clinic BP readings 
37
.  One fourth of the children with HT can be missed when only 
Home BP Monitoring is used. Thus ABPM is the best means of identifying all CKD children 
20 
 
with hypertension. This method also avoids a mistaken diagnosis of hypertension in those with 
only white coat HT.  
In India, Sinha et al have shown the usefulness of ABPM amongst children with CKD 
38
.  
Suggested Schema for APBM in Children 
39
:  
 
 
 
End Organ Damage: 
ABPM is a predictor for target organ damage and can predict future outcomes.  
Left Ventricular Hypertrophy co-relates best with SBP and BP Index detected by ABPM 
39
. 
ABPM picks up early loss of nocturnal dip in BP and it is a better predictor of end organ damage 
37
. Loss of normal nocturnal dipping is associated with greater proteinuria and poorer renal 
function 
40,41
. ABPM was found to be a better predictor of proteinuria than home BP, single clinic 
BP by automated device, or standard BP monitoring 
42
.  
 
ABPM Indices Measured: 
Average BP readings: Mean, Daytime, Night time 
21 
 
BP Load: the percentage of valid ambulatory BP measures above the 95th percentile of BP for 
age, gender, and height. BP Load of 25-30% is considered significant.  
BP Index: The average BP for each patient divided by the 95
th
 centile BP value specific for that 
patient.  
Nocturnal Dipping: >= 10% fall in SBP and DBP from daytime to night time. It can be 
calculated by ([mean daytime ABPM−mean nighttime ABPM] / (mean day ABPM) ×100) 
 
Normative ABPM Data: 
There is a separate normative data for pediatric ABPM which is different from the usual Clinic 
BP guideline in children 
37,43–46
 . The largest study was done by O Sullivan et al amongst healthy 
school children in Newcastle 
45
. The data is arranged according to gender, height and age. We 
have used the data by Wuhl et al as recommended by the American Heart Association 
37
 to 
interpret our ABPM readings because normative data for Indian children are not available. 
 
 
Country Author Number of  
children 
Age Groups 
(Years) 
Reference 
Germany: Escape Trial  
Group 
Wuhl et al 118 3-19 
37
 
USA Harshfield GA et al 300 10-18 
43
 
Spain Lurbe et al 241 6-16 
44
 
UK Newcastle O Sullivan et al 1121  
45
 
Germany Reichert H et al 564 9-13 
46
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LEFT VENTRICULAR DYSFUNCTION: 
Children with CKD are known to have cardiac dysfunction 
47
. Yet there are few deaths amongst 
children with CKD due to cardiovascular diseases. Thus we need other intermediate end points to 
determine cardiovascular risks amongst children. Left Ventricular Hypertrophy is a predictor of 
mortality amongst adults with CKD 
48
.  Left Ventricular Hypertrophy helps to improve cardiac 
contractility and lower wall stress in view of increased after-load and preload 
49
.   
Many studies in adults have shown that CKD leads to systolic dysfunction and progressive heart 
failure 
50
.  In children however systolic LV Dysfunction rarely occurs 
5152
. 
 Mark Mitsnefes et al conducted a study of LV Dysfunction amongst 25 children with CKD and 
found that LV Mass Index, LV Performance and contractility at rest was increased in children 
with CKD. The children on dialysis had lower contractile reserve during exercise which might be 
an early indicator for severe systolic dysfunction. They also demonstrated that LV dysfunction 
developed early in CKD and progressively worsens with decreasing levels of GFR 
49
.  
Amongst children on dialysis worse LV dysfunction was seen in children on hemodialysis with 
respect to children on peritoneal dialysis 
53
.  
LVM Definitions: 
LVM is calculated according to the formula by Devereux 
54
: 
LVM (g) = 0.8 {1.04 [(LVEDD + PWT +IVST)3 -(LVEDD)3] + 0.6}  
LVEDD: Left Ventricular End Diastolic Diameter 
PWT: Posterior Wall Thickness 
IVST: Inter Ventricular Septal Thickness 
LVH was earlier defined as LVM > 38.6 gm/m2.7 based on the study by National High 
Blood Pressure Education Program Working Group on High Blood Pressure in Children 
23 
 
and Adolescents 
55
. But this did not take into account variations due to the height, age or 
gender of the child.  Khoury et al defined LVH as LVMI greater than the 95
th
 centile for 
gender and chronological age 
56
.  Whereas Foster et al took LVH  
as LVMI greater than 95
th
 cenitle for height age (age of the child with the same height 
growing at 50
th
 height percentile) 
57
. Here we have followed the last definition since it 
most accurately represents the relation of height to LVM.  
Country Authors Number 
 of  
children 
Results Reference 
USA  
New York  
Cincinnati 
De Simone 
 et al 
1992 
444  
(4-23 mo) 
LVM/Ht^2.7 had least least correlation with 
Ht 
58
 
USA 
Cincinnati 
Daniels  
et al 1995 
192  
(6-17 yrs) 
LVM/Ht ^2.7 best correlated with  
LVM/LBM 
59
 
USA 
Boston and  
Cincinnati  
Foster et al 
2008 
440  
(0-21 yrs) 
LVMI inversely correlated with Ht, LVM for Ht 
centile curves superior to LVMI for  
normalizing LVM in children 
57
 
USA  
Cincinnati  
Khoury 
et al 2009 
2273 
(0-18 yrs) 
LVMI for age centile curves superior to  
LVMI in normalizing LVM in children 
56
 
 
Left Ventricular Hypertrophy is defined as LV mass greater than 95
th
 centile for age, sex and 
height 
60
. 
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 Left Ventricular Mass Index was calculated to account for LVH and body size. It was 
calculated by dividing the LV Mass by the height raised to a power of 2.7. 
 The relative wall thickness was measured to determine if LVH was concentric or eccentric. 
Concentric LVH was defined as increased LVM Index with RWT > 0.41, whereas eccentric LVH 
was defined as increased LVM Index with normal RWT < 0.41 
61
.  Concentric hypertrophy 
results in stiffer LV and impaired diastolic filling. Eccentric hypertrophy is more likely due to 
volume overload.  
All children with CKD have diastolic dysfunction, which is worse in children on dialysis. This 
diastolic dysfunction can lead on to LV Dysfunction and later to CCF.  
 
ATHEROSCLEROSIS: 
Atherosclerosis is one of the known classical risk factors for cardiovascular disease 
62
. It is 
commonly seen in children with CKD, but the stage of CKD when atherosclerosis begins is not 
exactly known. Intima/ media thickness of large arteries such as the carotid artery determined by 
Doppler studies is an early predictor of atherosclerosis. Normal children almost never have 
atherosclerosis. Thus any amount of atherosclerosis detected can be attributed to be secondary to 
CKD. The Carotid intimal thickness can be measured by non-invasive methods like USG 
Doppler or by CT of the neck 
63
. UG Doppler is preferred since there is no risk of radiation 
exposure.  
Carotid Intimal Medial thickness(c IMT) is measured in the internal carotid artery at a fixed point 
20 mm distal to the carotid bifurcation. It is compared to age and sex matched normograms 
64
.  
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In a study done by Jun Oh et al amongst 39 adults with childhood onset of CKD, they found that 
coronary calcification was present in 92% of patients and carotid intimal thickness was increased 
when compared to age and sex matched controls. The carotid intimal thickness strongly 
correlates with the Calcium X Phosphorus product and the cumulative dialysis duration 
65
. It is 
also related to the prevalence of Chlamydia pneumoniae, increased CRP, PTH levels and levels 
of plasma homocystine 
66
.  The calcium-phosphorus product also correlates with the vascular 
remodeling and non-compliance of vessels 
67
.  
In a study done in pediatric CKD patients who died, as many as 60% were found to have 
evidence of soft tissue calcification
68
. The degree of calcification was directly correlated with 
Vitamin D supplementation. Children who received Calcitriol had increased calcification when 
compared to those who received Dihydrotachysterol or D2, D3 supplementation only.  
The risk of early onset atherosclerosis with mortality due to cardiovascular causes is 10-30 times 
greater in children on dialysis than in children without CKD 
67
. Children on hemodialysis had 
greater elevation of carotid IMT than those on peritoneal dialysis 
69
. Post renal transplantation 
children had greater carotid IMT when compared to those on dialysis 
70
.  
A summary of a review of studies showing a significant increase in c IMT amongst children with 
CKD compared to controls 
26
 is presented below: 
 
 
DYSLIPIDEMIA: 
Elevated Lipid profile is a known classical risk factor for cardiovascular disease. Children with 
CKD have been found to have abnormally elevated lipid profiles as compared to age and sex 
matched controls 
65
. In a study by Rafat M Muhaisen et al in Gaza amongst 112 children studied, 
26 
 
children with CKD showed significantly higher levels of cholesterol (163.6±39.8 vs. 141.8±24.2 
mg/dL, P<0.0001), triglycerides (145.5±67.1 vs. 82.9±39.8 mg/dL, P<0.0001), low-density 
lipoprotein (92.6±31.9 vs. 72.5±19 mg/dL, P<</i>0.0001). These children were also found to 
have lower levels of high-density lipoprotein (41.9±11.0 vs. 52.7±11.7 mg/dL, P<0.0001) 
compared to controls 
71
.  
It is evident that patients on hemodialysis are better off so far as several lipid parameters are 
concerned 
The usefulness of statin therapy has been proven amongst adults with early CKD but not amongst 
those requiring dialysis. The AURORA 
72
 and the 4D trial (Die Deutsche Diabetes Dialysis 
Study) 
73
 
 Have shown that statins have the required lipid lowering effect, but they do not significantly 
reduce mortality due to cardiovascular causes amongst adults on dialysis 
74
.  
Thus dyslipidemia is another modifiable risk factor for cardiovascular disease in children with 
CKD which needs to be studied in greater detail.  
Pathophysiology of hypertriglyceridemia in uremia 
75
:  
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The present study will help in outlining the cardiovascular risks amongst children with CKD 
form a teaching hospital in India. The present study was undertaken because no studies have been 
done so far in India. There is no Cochrane Review available on the risks of cardiovascular disease 
amongst children with CKD.   Thus more studies and systematic reviews are required in this 
field.  This will increase our knowledge base about the cardiovascular risks in children with 
CKD, help identify children with CKD who are at risk for cardiovascular disease and thus help in 
improving our management of these risk factors. Children with CKD are living longer with better 
medical management and Renal Replacement Therapy. In order to prevent cardiovascular 
morbidity and mortality, we need to be aware that CKD children have increased cardiovascular 
risks and we need to manage these risk factors better  
 
 
  
 
METHODOLOGY 
 
 
28 
 
 
METHODOLOGY 
 This was a prospective cross-sectional study conducted in the Pediatric Department of Christian 
Medical College and Hospital Vellore from Oct 2011- Nov 2012. CMCH is a tertiary care center 
located in South India which is a referral center for local patients as well as patients from all over 
India.  
In our hospital 6000 children come to the Pediatric Nephrology OPD each year. Out of these 50 
new cases of CKD were seen from March 2010- September 2011. Thus there are a large number 
of children with CKD who can be included in our study.  
Study Subjects: 
Children, aged 1-18 years with Chronic Kidney Disease who presented to the Pediatric 
Nephrology OPD, General Pediatric OPD or Inpatient Facilities were recruited.   
Chronic Kidney Disease as defined by the National Kidney Foundation in 2002:  (1) kidney 
damage for >3 months, as confirmed by kidney biopsy or markers of kidney damage, with or 
without a decrease in glomerular filtration rate (GFR), or (2) GFR <60 mL /min/ 1.73 m^2 for >3 
months, with or without kidney damage 
14
.  
The Glomerular Filtration Rate was calculated according to the Schwartz Formula for children < 
15 years old. For older children the Cockcroft-Gault formula would be used to estimate GFR.  
The children were divided into the following groups according to their Glomerular Filtration 
Rates:  
Stage 3 disease — GFR between 30 and 59 mL/min per 1.73 m^2 
Stage 4 disease — GFR between 15 and 29 mL/min per 1.73 m^2 
Stage 5 disease — GFR of less than 15 mL/min per 1.73 m^2 or end-stage renal disease (ESRD) 
29 
 
 
Children with GFR < 15 ml/min/1.73 m^2 on Dialysis  
Inclusion Criteria: 
All children with CKD and GFR < 60 ml/min/1.73 m^2 aged 1-18 years will be recruited after 
parental consent 
Exclusion Criteria: 
Any child with Renal, other solid organ, Bone marrow Transplantation  
Cancer/ HIV diagnosed during the past 12 months 
Genetic Syndromes 
Presence of any congenital/structural heart disease or myocardial disease 
Methodology: 
Informed consent was taken from all parents by the Principal Investigator (Annexure I). A 
detailed history including demographic data, duration and course of disease, treatment details was 
taken. A complete physical examination was done including anthropometric data, edema, Clinic 
Blood Pressure recordings.  Information was entered into a Clinical Research Form (Annexure 
II).  
Routine Blood tests (Hemoglobin, Sodium, Potassium, Creatinine, Urea, Calcium, Phosphorus, 
Alkaline Phosphatase, Bicarbonate, Parathyroid hormone levels) were noted using the P 800 
Roche Hitachi Modular System.  The mean of 3 clinic BP readings over the previous 3 visits 
were recorded. Ambulatory BP recording was performed for each child over a 24 hour period 
using the Spacelabs Healthcare (040-1546-00) machine. ECHO was done to determine Left 
Ventricular Dysfunction (LV mass, LV Mass Index, Relative Wall Thickness). The Philips IE 33 
model with 12 size pediatric probe was used. 
30 
 
The study was approved by the Institutional Review Board of CMC Hospital Vellore.  
Ambulatory BP Monitoring:  
ABPM was monitored for every child using the Spacelabs Healthcare (040-1546-00) machine. 
The appropriate sized BP cuff was attached to the non-dominant arm of the child. BP readings 
were recorded for a 24 hour period. The exact sleep and wake timings of children were not 
determined, and it was assumed that they sleep between 10 pm to 6 am.  Subjects were asked to 
continue all their normal daily activities. BP recordings were measured every 20 minutes during 
the day time and every hourly at night time.  
Ambulatory HT was defined as BP greater than the 95
th
 centile for age and height 
39
 as provided 
in Annexure V. BP load was calculated as the percentage of BP readings above the 95
th
 centile. 
Nocturnal dipping was defined as a > 10% difference between day time and night time BP 
readings. Ambulatory BP Index was calculated as the average BP of the child divided by the 95
th
 
centile Ambulatory BP for that particular age, height and gender.  
ECHO: 
ECHO was done for every child using the Philips IE 33 model with 12 size pediatric probes. The  
ECHO was performed by a trained technician or doctor according to their protocol. The  
parameters recorded were LVID, LV Posterior Wall thickness, Inter Ventricular Septal  
Thickness, Relative Wall Thickness, Fractional Shortening, Ejection Fraction, Maximum 
E velocity, Maximum A velocity and the E/A ratio. 
LV Hypertrophy was defined as the LV Mass greater than the 95
th
 centile for age, sex and  
Height as shown in Annexure IV.  
These were used to calculate the LV Mass according to the Devereox formula. The LV Mass  
Index was calculated as well as the LVM/Ht^2.7.  
31 
 
Sample Size Estimation: 
N, Number in each arm of study = 2 X SD^2 (Za+Zb)^2 
                                                                (m1-m2)^2 
SD= Standard Deviation 
Za= 1.96 
Zb= 0.84 
M1=Mean 1 
M2= Mean 2 
LVMI of children with CKD not requiring Dialysis 37.7 +/- 9.9 
LVMI of children with CKD with Dialysis 45.7 +/- 10.7 
N = 2 X 10 X 10 X (2.8)^2  = 24.5 
                    (8)^2 
Thus 25 children need to be recruited in each arm of the study. Since we have two arms in the 
study the total sample size was estimated to be 50 children.  
Data Analysis:       
 The data collected was analyzed using SPSS software and chi square tests of significance were 
done.  
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RESULTS 
 
Forty Six children with Chronic Kidney Disease were recruited from the Pediatric 
Nephrology Unit of Christian Medical College Vellore during the study period Nov 2011 
to Nov 2012.  
 
The cardiovascular risk factors were analyzed in all these children.  
 
Details of the results obtained are given below: 
 
SEX DISTRIBUTION 
 
Table 1 
 
Sex Number Percentage 
Boys 37 80.4 
Girls 9 19.6 
Total 46 100 
 
Figure 1 
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Majority 37/46 (80.4%) of the children with CKD were males. 
Male: Female Ratio was 4.1:1 
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AGE DISTRIBUTION 
 
Table 2 
 
Age Group Number Percentage 
1-6 yrs 6 13.0 
>6yrs to 9yrs 6 13.0 
>9 yrs to 12 yrs 13 28.3 
> 12 yrs to 15 yrs 17 36.9 
>15 yrs to 18 yrs 4 8.6 
 
 
Figure 2 
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Majority of children presented above 9 years of age 
36.9% (17/46) of the children were in the age group of 12-15 years 
28.3% (13/46) were 9-12 years old 
13% (6/46) were 1-6 years old and 6-9 years old respectively 
8.6% (4/46) children were > 15 years of age 
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DEMOGRAPHY 
 
Table 3 
 
Country Number Percentage 
India 44 95.6 
Bangladesh 2 4.3 
Total 46 100 
 
Figure 3  
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Of the 46 children with CKD studied, 44/46 (96%) were from India.  
2/46 (4%) of the children were from Bangladesh. 
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DEMOGRAPHY FROM INDIA 
 
Table 4 
 
State Number Percentage 
Tamil Nadu 21 47.7 
West Bengal 8 18.2 
Andhra Pradesh 6 13.6 
Jharkhand 2 4.5 
Maharashtra 1 2.3 
Madhya Pradesh 1 2.3 
Odissa 1 2.3 
Chattisgarh 1 2.3 
Bihar 1 2.3 
Assam 1 2.3 
Manipur 1 2.3 
Total 44 100 
 
Figure 4 
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Of the 44 children from India, 21/44(47.7%) were from Tamil Nadu. 
 
Amongst the children from other states, 8/44 (18.2%) were from West Bengal, 
6/44 (13.6%) were from Andhra Pradesh, 2/44 (4.5%) were from Jharkhand and 1 (2.3%) 
child each from Maharashtra, Madhya Pradesh, Odissa, Chattisgarh, Bihar, Assam and 
Manipur.  
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CAUSES OF CHRONIC KIDNEY DISEASE 
 
Table 5 
 
Cause Number Percentage 
Cystic 1 2 
Glomerular 7 15 
Tubular 0 0 
Dysplastic 16 35 
Uropathic 22 48 
Total 46 100 
 
Figure 5 
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Obstructive Uropathy was the commonest cause of CKD amongst children 22/46 (48%) 
Dysplastic kidneys were the second most common cause of CKD 16/46 (35%) 
Glomerular causes were found in 7/46 (15%) of children with CKD 
Cystic causes were found in 1/46 (2%) of children with CKD 
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STAGES OF CHRONIC KIDNEY DISEASE 
 
Table 6 
 
Stage of CKD Number Percentage 
CKD Stage 3 18 39.1 
CKD Stage 4 18 39.1 
CKD Stage 5 and Dialysis 10 21.7 
Total 46 100 
 
Figure 6 
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Of the 46 children with CKD, 18/46 (39.1%) were in CKD Stage 3 and 4 respectively, 
while 10/46 (21.7%) had CKD Stage 5 or were on Dialysis.  
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Out of all the 46 children studied, 42 (91.3%) were found to have cardiovascular risk 
factors. Details are given below: 
 
 
Cardiovascular Risks Percentage in children with CKD (%) 
Low BMI 30/42 
(71.4%) 
Anemia 22/42 
(52.4%) 
Proteinuria 18/42 
(42.9%) 
Abnormal Ca X PO4 Product 20/42 
(47.6%) 
 
 
Further analysis was carried out to analyze the cardiovascular risks amongst children with 
CKD. The children were divided into two groups for the purpose of analysis: 
1. Children with CKD not requiring Dialysis 
2. Children with CKD on Dialysis  
The complications of CKD were compared between the two groups.  
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Body Mass Index 
 
Body Mass Index was plotted for each child according to the WHO BMI charts.  
A z score from -1 to +1 was considered normal. Further z scores were all abnormal. 
Lower z scores correlated with under-nutrition, while higher z scores signified obesity.  
 
Table 7 
 
BMI CKD without 
Dialysis 
CKD with 
Dialysis 
Total 
-1 to +1 Z score 10  
(28.6%) 
2  
(18.2%) 
12 
-2 to +2 Z score 14  
(40%) 
4  
(36.4%) 
18 
-3 to + 3 Z score 10  
(28.6%) 
5  
(45.5%) 
15 
-4 to + 4 Z score 1  
(2.9%) 
0 1 
Total 35 11 46   
 
Figure 7 
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All children except one had normal to low BMI. Only one child had obesity with BMI of 
27.3.  
Though children in both groups had low BMI, those on dialysis had a lower BMI (81.9%) 
compared to children in the non-dialysis group (71.5%). 
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Children with CKD on Dialysis and those not requiring Dialysis 
 
Table 8 
 
Dialysis Status Number Percentage 
CKD not requiring Dialysis 35 76 
CKD with Dialysis 11 23.9 
Total 46 100 
 
Figure 8 
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35/46 (76%) of children with CKD were not on Dialysis. 
11/46 (23.9%) of children with CKD were on Dialysis.  
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Calcium Phosphorus Product and CKD 
 
Table 9 
 
 CKD without 
Dialysis 
CKD with Dialysis P Value 
Ca X PO4 Product 36.39 42.95 0.227 
 
Figure 9 
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There was no significant difference between the Calcium X Phosphorus Product between 
children with CKD without Dialysis (Ca X PO4 36.39) and children requiring Dialysis  
(Ca X PO4 42.95 p=0.227). 
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Anemia and CKD 
 
Anemia is defined as hemoglobin levels less than 11 gm%.  
 
Table 10 
 
 Anemia Present Anemia Absent Total 
CKD without Dialysis 17/35 
(48.6%) 
18/35 
(51.4%) 
35 
CKD with Dialysis 8/11 
(72.7%) 
3/11 
(27.3%) 
11 
Total 25 21 46 
 
Figure 10 
 
Anemia and CKD
48.60%
72.70%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
CKD without Dialysis CKD with Dialysis
%
 w
it
h
 A
n
e
m
ia
Number= 46
 
 
There was no significant difference in the prevalence of anemia amongst children with 
CKD without Dialysis 17/35 (48.6%) and children on dialysis 8/11 (72.7%) (p=0.145). 
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Hyperkalemia and CKD 
 
Hyperkalemia was defined as Potassium levels greater than 5.5 mg/dl.  
 
Table 11 
 
 Hyperkalemia Present Hyperkalemia 
Absent 
Total 
CKD without Dialysis 6/35 
(17.1%) 
29/35 
(82.9%) 
35 
CKD with Dialysis 2/11 
(18.2%) 
9/11 
(81.8%) 
11 
Total 8 38 46 
 
Figure 11 
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There was significant difference in the prevalence of Hyperkalemia amongst children 
with CKD not requiring dialysis 6/35 (17.1%) and children on dialysis 2/11 (18.2%) 
(p=0.026). 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 Metabolic Acidosis and CKD 
 
Metabolic acidosis was defined as a serum bicarbonate level lower than 20 mg/dl. 
 
Table 12 
 
 Acidosis Present Acidosis Absent Total 
CKD without Dialysis 21/35 
(60%) 
14/35 
(40%) 
35 
CKD with Dialysis 6/11 
(54.5%) 
5/11 
(45.4%) 
11 
Total 27 19 46 
 
Figure 12 
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There was no significant difference in the prevalence of Metabolic Acidosis between 
children with CKD not requiring dialysis 21/35 (60%) and children on dialysis 6/11 
(54.4%) (p=0.508).  
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 Hyperphosphatemia and CKD 
 
Hyperphosphatemia was defined as serum Phosphorus levels greater than 5 mg/dl.  
 
Table 13 
 
 Hyperphosphatemia 
Present 
Hyperphosphatemia 
Absent 
Total 
CKD without Dialysis 7/34 
(20.6%) 
27/34 
(79.4%) 
34 
CKD with Dialysis 7/10 
(70%) 
3/10 
(30%) 
10 
Total 14 30 44 
 
Figure 13 
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There was a significant difference in the prevalence of Hyperphosphatemia amongst 
children with CKD not requiring dialysis 7/34 (20.6%) and children on dialysis  
7/10 (70%) (p=0.006).  
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Metabolic Bone Disease and CKD 
 
Metabolic Bone Disease was considered in all children with CKD who had Hyper-
parathyroidism with serum PTH levels greater than 250 mg/dl.  
 
Table 14 
 
 Hyper 
parathyroidism 
Present 
Hyper 
parathyroidism 
Absent 
Total 
CKD without Dialysis 12/35 
(34.3%) 
23/35 
(65.7%) 
35 
CKD with Dialysis 7/10 
(70%) 
3/10 
(30%) 
10 
Total 19 26 45 
 
Figure 14 
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Children on dialysis had a greater prevalence of Metabolic Bone Disease 7/10 (70%) as 
compared to children with CKD not requiring dialysis12/35 (34.3%) (p=0.05).  
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 Proteinuria and CKD 
 
Proteinuria was defined as a Urine protein/Creatinine ratio of greater than 0.03. 
 
Table 15 
 
 Proteinuria Present Proteinuria Absent Total 
CKD without Dialysis 18/20 
(90%) 
2/10 
(10%) 
20 
CKD with Dialysis 2/3 
(66.6%) 
1/3 
(33.3%) 
3 
Total 20 3 23 
 
Figure 15 
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There was no significant difference in the prevalence of Proteinuria between children 
with CKD not requiring dialysis 18/20 (90%) and children on dialysis 2/3 (66.6%) 
(p=0.356).  
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Hypertension and CKD 
 
Hypertension was assessed by Clinic BP readings and by Ambulatory BP Monitoring 
over a 24 hour period in all children.  
Table 16 
 
Hypertension Present Absent Total 
Clinic HT 10/46 
(21.7%) 
36/46 
(78.3%) 
46 
ABPM 42/46 
(91.3%) 
4/46 
(8.7%) 
46 
 
Figure 16 
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Using Clinic BP alone 10/46 (21.7%) of children with CKD were found to be 
hypertensive. 
With the additional usage of ABPM 42/46 (91.3%) of children with CKD were found to 
be hypertensive, an additional 32/46 (69.5%) were found to have masked hypertension.  
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Class of CKD and Hypertension 
 
Table 17 
 
Class of CKD Clinic HT ABPM HT Total 
Class 3 CKD 4/18 
(22.2%) 
15/18 
(83.3%) 
18 
Class 4 CKD 1/18 
(5.5%) 
17/18 
(94.4%) 
18 
Class 5 CKD and Dialysis 5/10 
(50%) 
10/10 
(100%) 
10 
Total 10 42 46 
 
Figure 17 
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ABPM was able to detect more hypertension across all classes of CKD wrt clinic BP 
readings.  
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Clinic BP and Number on Anti-Hypertensive Medications 
 
The prevalence of Clinic HT was compared with the number of anti hypertensive 
medications that the children were taking.  
 
The adequacy of BP control with anti-hypertensive medications was assessed.  
 
Table 18 
 
 No Anti HT Anti HT Present Total 
Clinic BP Normal 10/12  
(83.3%) 
26/34  
(76.4%) 
36 
Clinic HT 2/12  
(16.6%) 
8/34  
(23.5%) 
10 
Total 12 34 46 
 
Figure 18 
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Of those with Clinic Hypertension, 2/12 (16.6%) were not on any anti hypertensive 
medications, while 8/34 (23.5%) were on anti hypertensive medications.  
 
2/10 (20%) of children were newly detected to have Clinic HT. 
 
8/10 (80%) of the children with Clinic HT were on anti hypertensive medications and 
their BP was not adequately controlled.   
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Ambulatory Hypertension and Anti Hypertensive medication Usage 
 
The prevalence of Ambulatory HT was compared with the number of anti hypertensive 
medications that the children were taking.  
 
The adequacy of BP control with anti-hypertensive medications was assessed.  
 
Table 19 
 
 No Anti HT 
Medications 
Anti HT 
Medications 
Present 
Total 
Ambulatory HT 
Absent 
0 4/34  
(11.8%) 
4 
Ambulatory HT 
Present 
12/12  
(100%) 
30/34  
(88.2%) 
42 
Total 12 34 46 
 
Figure 19 
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There was no significant difference between the prevalence of Ambulatory HT amongst 
those on anti HT medications 30/34 (88.2%) or those not on any anti HT medications 
12/12 (100%)  (p= 0.284). 
  
Four children in whom Ambulatory HT was absent were on anti hypertensive 
medications and their HT was adequately controlled.  
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Erythropoietin usage vs Hypertension 
 
Table 20 
 
 Erythropoietin Number Mean Std. Deviation 
SBP Absent 32 112.53 14.418 
 Present 14 118.00 11.429 
DBP Absent 32 70.00 11.433 
 Present 14 76.21 9.316 
MBP Absent 32 84.44 11.086 
 Present 14 90.14 9.330 
 
 Figure 20 
 
 
 
Children on treatment with Erythropoietin were found to have higher SBP, DBP and 
MBP compared to those not receiving Erythropoietin.  
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Cardiovascular Dysfunction 
 
ECHO was done in all children to determine LV Dysfunction and to calculate the LV 
Mass. 
 
LV Hypertrophy was defined as LV Mass greater than 95
th
 centile for age and sex.  
 
Here we have compared the prevalence of LVH as per the Class of CKD. 
 
LVH and CKD 
 
Table 21 
 
 CKD without Dialysis CKD with Dialysis Total 
LVH Absent 28/35 
 (80%) 
5/11 
 (45.4%) 
33 
LVH Present 7/35  
(20%) 
6/11  
(54.5%) 
13 
Total 35 11 46 
 
Figure 21 
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There was a significant difference in the prevalence of LVH amongst children on dialysis 
6/11 (54.4%) and children with CKD not requiring dialysis 7/35 (20%) (p=0.036).  
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LVH v s ABPM 
 
Ambulatory HT is determined using 3 indices: Lack of Nocturnal BP Dipping, BP Load 
and BP Index. Any one of the indices are adequate to diagnose Ambulatory HT.  
 
We determined the correlation between the number of ABPM Indices and the prevalence 
of LVH.  
Table 22 
 
 ABPM Total 
 0 Indices 1 Index 2 Indices 3 Indices  
LVH Absent 3/33 
(9.1%) 
17/33 
(51.5%) 
9/33 
(27.3%) 
4/33 
(12.1%) 
33 
 Present 1/13 
(7.7%) 
2/13 
(15.4%) 
4/13 
(30.8%) 
6/13 
(46.2%) 
13 
Total 4 19 13 10 46 
 
Figure 22 
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There is significant correlation between the number of ABPM indices present and the 
Percentage with LVH (p=0.046). 
When no ABPM index is present, only 7.7% of subjects had LVH. 
When 1 ABPM index is present 15.4% of subjects had LVH. 
When 2 ABPM indices are present 30.8% of subjects had LVH. 
When all 3 ABPM indices are present 46.2% of subjects have LVH. 
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LVH vs Number of anti hypertensive medications 
 
Table 23 
 
 LVH Total 
  Absent Present  
Number of anti 
hypertensive 
medications 
0 
12/12 
(100%) 
0 12 
  1 15/16 
(93.8%) 
1/16 
(6.3%) 
16 
  2 2/9 
(22.2%) 
7/9 
(77.8%) 
9 
  3 4/7  
(57.1%) 
3/7 
(42.9%) 
7 
  4 
0 
2/2 
(100%) 
2 
Total 33 13 46 
 
Figure 23 
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There is a significant correlation between the number of Anti-Hypertensive Medications 
taken and the percentage of children with LVH (p=<0.001). 
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LV Mass vs Dialysis Status 
 
Table 24 
 
 CKD without 
Dialysis 
Mean (SD) 
CKD with 
Dialysis 
Mean (SD) 
P 
value 
Difference between 2 
means with 95
th
 % CI 
LV Mass 88.7 (45.77) 
 
142.6 (61.9) 0.003 53.9 (19.16-88.7) 
 
Figure 24 
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There was a statistically significant difference between the LV Mass of those children 
with CKD not requiring Dialysis (88.7 gm) and those on Dialysis (142.6 gm p= 0.003).  
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LVMI vs Dialysis Status 
 
Table 25 
 
 CKD without 
Dialysis 
Mean (SD) 
CKD with 
Dialysis 
Mean (SD) 
P Value Difference 
between 2 
means with 
95
th
 % CI 
LVMI 42.5 (24.6) 
 
64 (34.5) 0.026 21.5 (2.6-40.3) 
 
Figure 25 
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There was a statistically significant difference between the LVMI of those children with 
CKD not requiring Dialysis (42.5 gm/m^2.7) and those on Dialysis (64 gm/m^2.7 p= 
0.026).  
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
Fractional Shortening and CKD 
 
Table 26 
 
 CKD without 
Dialysis  
Mean (SD) 
CKD with Dialysis 
Mean (SD) 
P Value 
Fractional 
Shortening 
32.99  
(3.55) 
27.35 
(6.29) 
0.015 
 
Figure 26 
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There is a significant difference between the percentage of Fractional Shortening between 
children with CKD not requiring dialysis 32.99 %, and those on dialysis 27.35% 
(p=0.015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
Ejection Fraction and CKD 
 
Table 27 
 
 CKD without 
Dialysis 
Mean (SD) 
CKD with Dialysis 
Mean (SD) 
P value 
Ejection Fraction 
(%) 
62.3 
(4.86) 
53.0 
(10.73) 
0.017 
 
Figure 27 
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There was a statistically significant difference in the Ejection Fraction between children 
with CKD not requiring dialysis 62.3% and those on dialysis 53% (p= 0.017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
 
E/A Velocity and CKD 
 
Table 28 
 
 CKD without 
Dialysis 
Mean (SD) 
CKD with Dialysis  
Mean (SD) 
P Value 
E/A Velocity 1.56  
(0.27) 
1.46 
(0.46) 
0.696 
 
Figure 28 
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There was no statistically significant difference in the E/A Velocity amongst children 
with CKD not requiring Dialysis 1.56, and those on dialysis 1.46 (p=0.696).  
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Comparison between children with CKD not requiring dialysis and Children on 
Dialysis 
 
Table 29 
 
PATIENT CHARACTERISTICS  
PARAMETERS 
CKD without Dialysis 
Mean (SD) N= 35 
CKD with Dialysis 
Mean (SD) N=11 P-value 
Age (yrs) 11.26 (3.48) 11.82 (3.03) 0.633 
Sex (male) 72.20% 90.00% 0.236 
Height (cm) 133.38 (20.01) 137.46 (19.19) 0.554 
Weight (kg) 29.81 (11.87) 29.93 (11.69) 0.978 
BMI (kg/m^2) 16.14 (3.16) 15.24 (2.33) 0.39 
BSA 1.05 (0.27) 1.07 (0.28) 0.795 
Stated Duration of 
CKD (mo) 
73.8 (54.31) 27.09 (37.11) 0.004 
Hypertension (%) 42.9 90.9 0.005 
 
Table 30 
 
PATIENT CHARACTERISTICS – MEDICATIONS 
PARAMETERS 
CKD without Dialysis 
Mean N= 35 
CKD with Dialysis 
Mean N=11  
P-value 
ACEI 57.10% 36.40% 0.196 
ARB 11.40% 27.30% 0.207 
CCB 28.60% 81.80% 0.003 
B-blockers 8.60% 18.20% 0.343 
AB 2.90% 36.40% 0.009 
Vasodilators 2.90% 18.20% 0.138 
Calcium 77.10% 81.80% 0.553 
Rocaltrol 60.00% 72.70% 0.349 
Iron 85.70% 90.90% 0.555 
Erythropoietin 22.90% 54.50% 0.056 
Soda bicarbonate 74.30% 63.60% 0.372 
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Systolic BP Vs LVMass 
 
The Systolic BP as measured by ABPM was found to correlate linearly with the LVMass 
(regression coefficient=0.481, p=0.001). Figure 31 
 
Diastolic BP Vs LVMass
The Diastolic BP as measured by ABPM was found to correlate linearly with the 
LVMass (regression coefficient=0.467, p=0.001).  Figure 32 
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Mean BP Vs LVMass 
 
The Mean BP as measured by ABPM was found to correlate linearly with the LVMass 
(regression coefficient=0.478, p=0.001). Figure 33 
 
SBP Vs LVM/Ht 
 
The Systolic BP as measured by ABPM was found to correlate linearly with the 
LVMass/Ht (regression coefficient=0.382, p=0.009). Figure 34 
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DBP vs LVM/Ht 
 
The Diastolic BP as measured by ABPM was found to correlate linearly with the 
LVMass/Ht (regression coefficient=0.412, p=0.004). Figure 35 
MBP vs LVM/Ht 
 
The Mean BP as measured by ABPM was found to correlate linearly with the LVMass/Ht 
(regression coefficient=0.403, p=0.005). Figure 36 
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SBP vs LVMI 
There was no significant correlation between the Systolic BP as measured by ABPM and the 
LVMI (regression coefficient=0.018, p=0.375). Figure 37 
 
 
DBP vs LVMI 
There was no significant correlation between the Diastolic BP as measured by ABPM and the 
LVMI (regression coefficient=0.048, p=0.143). Figure 38 
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MBP vs LVMI 
 
There was no significant correlation between the Mean BP as measured by ABPM and the LVMI 
(regression coefficient =0.035, p=0.214). Figure 39 
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LVMass vs Clinic SBP 
 
The Systolic BP as measured by Clinic Readings was found to correlate linearly with the 
LVMass (regression coefficient=0.451, p=0.002). Figure 40 
 
LVMass vs Clinic DBP 
 
The Diastolic BP as measured by Clinic Readings was found to correlate linearly with the 
LVMass (regression coefficient=0.367, p=0.012). Figure 41 
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LVM vs Stated Duration of Renal Failure 
There was no significant correlation between the stated duration of CKD and the 
LVMass(regression coefficient= -0.191, p=0.204). Figure 42 
 
LVM vs Stated Duration of Hypertension 
 
There was an apparent linear correlation between the Stated Duration of Hypertension and 
LVMass (regression coefficient=0.448, p=0.002). Figure 43 
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Univariate Analysis for variables that impact LVH:  
 
Table 44 
 
Variable P value Odds Ratio 
BP load 0.046 12.687 
Anemia 0.253 3.101 
BP Index 0.654 0.585 
Nocturnal Dipping 0.199 4.749 
Clinic BP 0.030 8.901 
Dialysis 0.866 0.841 
 
The univariate analysis showed that both Clinic BP readings (odds ratio 8.9) and BP Index as 
measured by ABPM (odds ratio 12.7) had significant contribution towards LVH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
DISCUSSION 
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DISCUSSION 
 
This study was conducted in the Pediatric Nephrology Unit of Christian Medical College Vellore 
which is a tertiary referral hospital situated in South India. The study was conducted in the time 
period from November 2011 to November 2012.  
 
Our study looked at the cardiovascular risk factors amongst children with Chronic Kidney Disease who  
had an estimated GFR of <60 ml/min/1.73m^2. Children with Chronic Kidney Disease are living longer  
due to renal replacement therapy in the form of dialysis and renal transplantation. With their increased  
life spans, they are more prone to developing cardiovascular risks. Many studies have showed that  
cardiovascular risks are the leading causes of death amongst children with CKD 
33,34,76,77
. Thus  
early identification of cardiovascular risks and their appropriate management can prolong life and  
prevent mortality.  
 
Forty six children with CKD were recruited in our study. Out of these 37/46 (80.4%) were males, 
while 9/46 (19.6%) were females (Table 1). The Male: Female ratio was found to be 4.1:1. This 
is similar to reports by Hari et al from AIIMS India who reported 225/305 (73.7%) males in their 
study 
78
. This unequal gender distribution can be explained by the gender selective health care 
seeking behavior of parents. In India, generally there is a bias towards the male child, thus once 
detected to have a chronic disease like CKD; parents are more likely to seek health care for male 
children than for female children.  
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The age distribution of the children was from 3 to 17 years. The maximum number of children  
was in the age group 12-15 years (17/46 36.9%), followed by 28.3% (13/46) in the 9-12 years 
age group, 13% (6/46) in the 1-6 years age group and 6-9 years age group and 8.6% (4/46) 
children > 15 years old (Table 2). 
 
Christian Medical College and Hospital is a tertiary care referral Hospital situated in South India. 
Amongst our children most were from India (44/46 95.6%) while 2/46 (4.3%) were from 
Bangladesh (Table 3). Amongst all the children from India the maximum number of children 
were from Tamil Nadu (21/46 47.7%) followed by West Bengal (8/46 18.2%) and Andhra 
Pradesh (6/46 13.6%). The rest of the children were from Jharkhand, Maharashtra, Madhya 
Pradesh, Odissa, Chattisgarh, Bihar, Assam and Manipur (Table 4).  
 
The commonest cause of CKD was found to be Obstructive Uropathy (22/46 48%) including 
Posterior Urethral Valve, Reflux Nephropathy and Neurogenic Bladder, followed by  
Dysplastic kidneys (16/48 35%), Glomerular disease (7/46 15%) and Cystic disease (1/46  
2%) (Table 5). There were no children with tubular causes of CKD. Data reported by Hari et al  
in a study done in AIIMS India in 2003 
16
 showed similar results with Obstructive Uropathy  
was the commonest cause (31.8%) followed by Chronic Glomerulonephritis (27.5%) and Reflux  
Nephropathy (16.7%).   
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The children were classified into various stages of CKD according to the KDOQI classification 
2
. According to the aim of our study only children with stage 3, 4 and 5 CKD were included in 
our study. There were 39.1% (18/46) children in both stage 3 and 4 CKD while there were 21.7 
% (10/46) children with stage 5 CKD or undergoing dialysis (Table 6).  
For further analysis all children with CKD were divided into two groups as shown in Table 8:  
1. Those with CKD not requiring Dialysis (35/46 76%) 
2. Those with CKD with Dialysis (11/46 23.9%) 
Amongst the 11 children on Dialysis 7/11 (63.6%) were on Continuous Ambulatory Peritoneal 
Dialysis while 4/11 (36.4%) were on Hemodialysis.  
The complications of children on CKD were compared between the two groups. 
Out of 46 children, 42 (93.1%) were found to have at least one cardiovascular risk factor.  
 
As part of the analysis of cardiovascular risks in children with CKD the nutritional status of 
children in the two groups was compared using BMI as an index. Our data showed low BMI in 
children when compared to other studies. Nutritional status of children with CKD is often 
suboptimal due to metabolic acidosis, uremia, nausea and ongoing chronic inflammation. Despite 
dietary counseling and regular follow up, most children had poor nutritional status. Despite 
adequate dialysis the nutrition of our children did not improve significantly. This could be due to 
the late disease presentation.  
 
 
 
 
74 
 
The Body Mass Index of children as compared to age and sex matched controls was found to be low in 
(Table 7). This is similar to the study done by D G Noone et al in which the BMI correlated with the  
degree of renal failure, with children with more advanced CKD having lower BMI 
79
. We did not find  
any statistically significant differences in the Body Mass Index amongst children with CKD without  
dialysis and those undergoing dialysis.  
 
There were 11/46 children on dialysis, while 35/46 children were on conservative management 
for CKD (Table 8). 
 
In other studies, the Calcium-Phosphorous Product has been found to be a marker of Carotid Intimal 
Medial thickness and thereby an early marker of atherosclerosis. In our study we did not find any  
Statistically significant difference in the Calcium-Phosphorus Product between the two groups, though 
the dialysis group had higher Ca X PO4 product (p= 0.227) (Table 9). 
 
The prevalence of Anemia was found to be higher amongst those on Dialysis (8/11 72.7%) 
compared to the non-dialysis group (17/35 48.2%). But this difference was not statistically 
significant (p= 0.145) (Table 10). This was in keeping with findings from Wong et al who found 
31% of children with stage 1 CKD to have anemia while 93.3% of those with stage 4 and 5 CKD 
had anemia (p=<0.01) 
17.
  
 
Erythropoietin was used in 14/46 (30.4%) children studied. Out of these 6/14 (42.8%) children 
were on dialysis. 64.3% (9/14) children on erythropoietin were still anemic.  
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The electrolyte status was assessed in all children. The main parameter considered was 
Hyperkalemia since most children had sodium values in the normal range. Hyperkalemia was 
detected in 18.2% (2/11) of children on dialysis compared to 17.1% (6/35) in non-dialysis 
children (p= 0.026) (Table 11). Wong et al have reported much lower rates of hyperkalemia with 
5.26% children with stage 3 CKD and 18.18 % children with stage 4 and 5 CKD found to have 
hyperkalemia 
17
. According to Alcazar et al the causes of hyperkalemia were drugs (ACEI, ARB, 
NSAIDS, and Heparin), constipation, prolonged fasting and metabolic acidosis 
22
. The causes of 
hyperkalemia were not elaborated in our patients, but may have been due to dietary factors and 
usage of ACEI.  
 
The prevalence of Metabolic Acidosis as defined by serum Bicarbonate levels below 20 mg/dl 
was found to be more amongst children not requiring dialysis (21/35 60%) compared to those on  
dialysis (6/11 54.4%) but it was not statistically significant (p= 0.508) (Table 12). In advanced 
stages of CKD these results matched those of Wong et al, with CKD stage 4 and 5 having  
54.55% metabolic acidosis 
17
. Wong reported much lower rates of metabolic acidosis amongst 
children with stage 3 CKD (7.89%).  
 
The phosphorus status is related to the dietary intake of children. There was a statistically 
significant difference in the prevalence of Hyperphosphatemia amongst the non-dialysis group 
(7/34 20.6%) and those on dialysis (7/10 70% p= 0.006) (Table 13). This is despite strict dietary 
restrictions and treatment with Phosphate binders. 
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Metabolic Bone Disease is am important complication of CKD. If poorly controlled, morbidity 
can be high due to renal osteodystrophy. The prevalence of Metabolic Bone Disease as defined 
by a serum Parathyroid hormone level >250 pg/dl was compared between the non-dialysis group 
(12/35 34.3%) and those on dialysis (7/10 70% p=0.05) which was found to be statistically 
significant (Table 14). Similar results were demonstrated by Wong et al who showed that the 
prevalence of metabolic bone disease was 43.3% in stage 3 CKD and 100 % in stage 4 and 5 
CKD 
17
.  
 
The prevalence of Proteinuria was higher amongst the non-dialysis group (18/20 90%) 
compared to those on dialysis (2/3 66.6%) but it was not statistically significant (p= 0.356) 
(Table 15). Wong et al defined proteinuria as urinary protein excretion greater than 1 gm/day.  
They found the prevalence of proteinuria to be 5.6% in stage 1 CKD and upto 40 % in stage 4 
and 5 CKD 
17
. Though the percentage of proteinuria amongst those on dialysis was less, the 
severity of proteinuria was greater in those on dialysis.  
 
The aim of our study was to determine the cardiovascular risk factors amongst children with 
CKD. The cardiovascular risks were determined using clinic BP readings, ABPM and ECHO. 
ABPM is not widely used in India to detect hypertension even though it’s the gold standard for 
detecting hypertension 
39
. There are 3 main indices used to assess BP by ABPM. The BP load 
tells about the percentage of BP readings above the 95
th
 centile for age, sex and height. The BP 
Index is the average BP for each patient divided by the 95
th
 centile BP value specific for that  
77 
 
patient. Nocturnal dipping indicated the normal fall in BP during night time which should be > 
10% 
39
. 
 
The prevalence of Hypertension was determined using both Clinic BP readings and with 24 hour  
Ambulatory BP Monitoring (Table 16). Clinic Hypertension was detected in 10/46 (21.7%) children.  
Using ABPM as the gold standard for detecting hypertension 91.3 % of children studied were found to  
be hypertensive (Table). This is in keeping with reports from Wong et al who found the prevalence of  
HT to be 63.29% in stage 1 CKD and upto 80 % in stage 4 and 5 CKD 
17
. Using ABPM a total of  
42/46 (91.3%) of children with CKD were found to be hypertensive. 
 
An additional 32 children were found to have Masked Hypertension using ABPM. Children  
with masked hypertension cannot be picked up by Clinic BP readings alone.  In a more recent study done  
by Mark Mitsnefes et al who found 38% children had masked HT 
24
. He also showed that 34% of  
children with confirmed HT had LVH while 20% of children with masked HT had LVH. By  
extrapolation routine BP recording in the Out Patient setting is missing upto 76.2% of HT in children  
with CKD.  
 
Hypertension is a very important cardiovascular risk. It’s also highly amenable to treatment. Thus early  
detection of hypertension and adequate control are paramount to preventing progression of  
cardiovascular risks.  
 
The prevalence of Hypertension was compared with the class of CKD. Our study showed that  
Hypertension increases with worsening classes of CKD (Table 17). In Stage 3 CKD clinic HT was  
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present in 4/18 (22.2%) while ambulatory HT was present in 15/18 (83.3%) children. Amongst children  
with Class 4 CKD only 5.5% (1/18) had Clinic HT as against 94.4% (17/18) with Ambulatory HT. While  
those with Class 5 CKD 5/10 (50%) were detected to had Clinic Hypertension and all 10 
(100%) had hypertension by ABPM. According to Mark Mitsnefes et al also the prevalence of  
hypertension amongst children on dialysis is as high as 52-75% 
3
. 
 
Despite normal Clinic BP readings ABPM still detects hypertension suggesting inadequate BP control.  
This goes to show that clinic BP readings are not sufficient to assess hypertension amongst children with  
CKD.  
 
16.6% (2/12) children with Clinic Hypertension were not on any anti hypertensive 
medications and had newly detected HT.  While 8/34 (23.5%) were on anti hypertensive 
medications, but with inadequate BP control (Table 18). 
 
Out of the children who were diagnosed to have Ambulatory HT 12/12 (100%) were not on any 
anti hypertensive medications and were newly detected to have hypertension. Whereas 30/34 
(88.2%) were on anti hypertensive medications but had inadequate BP control (Table 19).  
 
Erythropoietin is used amongst children with CKD to prevent anemia and reduce the number of blood  
transfusions. One of the known side effects of erythropoietin is hypertension. We looked at all the  
children with CKD who received treatment with Erythropoietin and compared with blood pressures with  
those not receiving erythropoietin. Children on treatment with erythropoietin were found to have greater 
SBP, DBP and MBP compared with those not receiving erythropoietin (Table 20). One confounder  
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could be that children with higher stages of CKD are likely to have more anemia and thus prescribed  
erythropoietin. These children also have a greater chance of being hypertensive in view of more  
advanced stage of CKD. Thus it is difficult to ascertain if the hypertension is secondary to erythropoietin  
usage or just part of the natural course of CKD.  
 
ECHO was used to determine LV Dysfunction amongst all children with CKD. The LV Mass 
was calculated using the Devereux formula 
54
 : 
LVM (g) = 0.8 {1.04 [(LVEDD + PWT +IVST)3 -(LVEDD)3] + 0.6}  
 
LV Hypertrophy was defined as LV Mass greater than 95
th
 centile for age and sex 
56
. Children 
with Dialysis had a significantly higher percentage of LVH (6/11 54.4%) compared to children 
without dialysis (7/35 20% p= 0.036) (Table 21). 
 
Hypertension is a major risk factor for cardiovascular disease amongst children with CKD. 
ABPM is the gold standard to determine hypertension. As more than one ABPM indices were 
taken into account, the prevalence of LVH increased (Table 22). When only 1out of 3 ABPM 
indices was present 2/13 (15.4%) had LVH, when 2 indices were present 4/13 (3.8%) and when 
all 3 indices were present 6/13 (46.2%) have LVH. This correlation was found to be statistically 
significant (p= 0.046). 
 
A literature search did not reveal any definite guidelines as to how many BP Indices need to be 
positive to indicate hypertension using ABPM. We need further studies in this field to correlate 
hypertension as defined by ABPM with LVH and to see at what exact cutoff LVH occurs. This 
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would help us define at what BP levels LVH is likely to set in and preventing this would be a 
target for adequacy of hypertensive control.  ABPM is considered the most predictive of end 
organ damage 
39
.  
 
 In our study we also found a significant correlation between the number of anti hypertensive 
medications used and the prevalence of LVH (p=<0.001). Children on 1 anti-HT had 6.3% 
chance of LVH, those on 2 anti-HT medications had 77.8%, those of 3 anti-HT medications had 
42.9% and those on 4 anti-HT medications had 100% chance of having LVH (Table 23). This 
emphasizes the importance of adequate hypertension control to prevent LVH.  
 
The LV Mass was compared between the non-dialysis group and children on dialysis. There was 
a statistically significant difference between the LV Mass of those children with CKD not 
requiring Dialysis (88.7 gm) and those on Dialysis (142.6 gm p= 0.003) (Table 24).  
 
The LVMass Index was compared between the two groups. The children undergoing dialysis 
were found to have a significantly higher LVMI (64 gm/m^2.7) compared to children in the non-
dialysis group (42.5 gm/m^2.7) (p= 0.026) (Table 25).  
 
The percentage of Fractional Shortening was found to be significantly less in the dialysis group 
(27.35%) compared to the non-dialysis group (32.99 %) (p=0.015) (Table 26).  
There was a statistically significant difference in the Ejection Fraction between children with 
CKD not requiring dialysis 62.3% and those on dialysis 53% (p= 0.017) (Table 27). 
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There was no statistically significant difference in the E/A Velocity amongst children with CKD 
not requiring Dialysis 1.56, and those on dialysis 1.46 (p=0.696) (Table 28).  
 
The ABPM readings for SBP, DBP and MBP were found to very significantly correlate with the LV 
Mass (p= 0.001) (Figure 31-33). The SBP, DBP and MBP readings also correlated with LVMass/ 
Height, but to a lesser extent than with LV Mass alone (p= 0.009, p=0.004, p=0.005 respectively) 
(Figure 34-36). The SBP, DBP and MBP were not found to correlate with the LVM Index (p=0.375, 
p=0.143 and p=0.214 respectively) (Figure 37-39). The Clinic SBP and DBP readings also correlated 
with the LVMass but to a lesser degree than the ABPM reading (p= 0.002 and p= 0.012 respectively) 
(Figure 40, 41). This leads on to show that ABPM is a better assessment of BP than clinic BP readings 
alone.  
 
It was postulated that longer duration of CKD would lead to greater cardiovascular risks in children.  
But the LV mass was not found to correlate with the Stated Duration of CKD (regression coefficient=  
-0.191, p=0.204) (Figure 42). This could be explained by the time gap between disease onset and when 
symptoms set it. Due to a lack of regular ante-natal screening for urinary tract anomalies or any routine 
screening of school children for CKD, children with CKD present late to medical attention when 
complications of CKD like anemia, metabolic bone disease, growth failure, fluid overload and acidosis  
have already set in. Thus there is a significant time lag between the onset of disease and when it is 
detected.  This could probably explain the lack of correlation between stated duration of CKD and 
LVMass. 
 
 If we were able to determine the true duration of CKD, it would probable correlate with degree of LVH.  
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There is an apparent linear correlation between the Stated Duration of Hypertension and LVMass  
(regression coefficient=0.448, p=0.002) (Figure 43). The longer the children have Hypertension the  
more they are predisposed to have LV overload and subsequent LVH. 
 
In a univariate analysis done to determine the factors contributing to LVH we found that only BP  
Load and Clinic BP were found to be statistically significant (p= 0.046 and p=0.030 
respectively) (Table 44). Children with significant BP Load had 12.7 times greater chance of  
having LVH. Children with Clinic HT had 8.9 times greater chance of having LVH. Lack of  
Nocturnal Dipping led to a 4.8 time greater chance of having LVH, while Anemia led to a 3.1  
times greater chance of having LVH. 
 
Amongst our children studied two children on dialysis died during our study period. Both children died  
at home and the exact cause of death could not be determined accurately. Their deaths too could have  
been due to cardiovascular causes.  
 
From our study we have learnt that regular ABPM and ECHO may be necessary in reducing the  
cardiovascular morbidity and mortality amongst children with CKD. We need to use these test as part of  
our routine practice to help our children with CKD to live longer and healthier lives.  
 
 
 
 
 
  
 
SUMMARY 
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SUMMARY 
 
1. This study was conducted in the Pediatric Nephrology Unit of Christian Medical College 
Vellore which is a tertiary referral hospital situated in South India.  
2. A total of 46 children with CKD were studies. 
3. The Male: Female Ratio was found to be 4.1:1. 
4. The age distribution of the children was from 3 to 17 years. The maximum number of 
children was in the age group 12-15 years (17/46 36.9%). 
5. Of the 46 children with CKD studied, 44/46 (96%) were from India. 2/46 (4%) of the 
children were from Bangladesh.  
6. Obstructive Uropathy was the commonest cause of CKD 22/46 (48%) followed by 
Dysplastic kidneys16/46 (35%). 
7. Of the 46 children with CKD, 18/46 (39.1%) were in CKD Stage 3 and 4 respectively, 
while 10/46 (21.7%) had CKD Stage 5 or were on Dialysis.  
8. The children were divided into two groups for the purpose of analysis: 
       Children with CKD not requiring Dialysis 
             Children with CKD on Dialysis  
9. Amongst the non-dialysis group 28.6 %( 10/35) had normal BMI, while 40% (14/35) had 
BMI +/- 2 Z scores, 28.6 % (10/35) had BMI +/- 3 Z scores while 2.9 % (1/35) had BMI 
+/- 4 Z scores. Amongst children on Dialysis 18.2 5 (2/11) had normal BMI, while 36.4 
% (4/11) had BMI +/- 2 Z scores, 45.5 % (5/11) had BMI +/- 3 Z scores.  
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    Amongst children on Dialysis 18.2 5 (2/11) had normal BMI, while 36.4 % (4/11) had      
BMI +/- 2 Z scores, 45.5 % (5/11) had BMI +/- 3 Z scores 
10. The calcium phosphorus product was found to be elevated in children with dialysis but it 
was not statistically significant compared to the non-dialysis group (p=0.227).  
11. There was no significant difference in the prevalence of anemia amongst children with 
CKD without Dialysis 17/35 (48.6%) and children on dialysis 8/11 (72.7%) (p=0.145). 
12. There was significant difference in the prevalence of Hyperkalemia amongst children 
with CKD not requiring dialysis 6/35 (17.1%) and children on dialysis 2/11 (18.2%) 
(p=0.026). 
13. There was no significant difference in the prevalence of Metabolic Acidosis between 
children with CKD not requiring dialysis 21/35 (60%) and children on dialysis 6/11 
(54.4%) (p=0.508).  
14. There was a significant difference in the prevalence of Hyperphosphatemia amongst 
children with CKD not requiring dialysis 7/34 (20.6%) and children on dialysis 7/10 
(70%) (p=0.006).  
15. Children on dialysis had a greater prevalence of Metabolic Bone Disease 7/10 (70%) as 
compared to children with CKD not requiring dialysis12/35 (34.3%) (p=0.05).  
16. There was no significant difference in the prevalence of Proteinuria between children 
with CKD not requiring dialysis 18/20 (90%) and children on dialysis 2/3 (66.6%) 
(p=0.356).  
17. Using Clinic BP alone 10/46 (21.7%) of children with CKD were found to be 
hypertensive. 
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18. With the additional usage of ABPM 42/46 (91.3%) of children with CKD were found to 
be hypertensive, an additional 32/46 (69.5%) were found to have masked hypertension.  
19. Out of the children diagnosed to have Clinic Hypertension, 2/12 (16.6%) were not on any 
anti hypertensive medications, while 8/34 (23.5%) were on anti hypertensive 
medications.  
20. There was no significant difference between the prevalence of Ambulatory HT amongst 
those not on anti HT medications 12/12 (100%) or users of anti HT medications 30/34 
(88.2%) (p= 0.284).  
21. There was a significant difference in the prevalence of LVH amongst children on dialysis 
6/11 (54.4%) and children with CKD not requiring dialysis 7/35 (20%) (p=0.036).  
22. There is significant correlation between the number of ABPM indices present and the 
Percentage with LVH (p=0.046). 
23. The Systolic BP, Diastolic BP and Mean BP was found to be higher amongst those children on  
       Erythropoietin when compared to children not using Erythropoietin.  
24. There was a significant difference in the prevalence of LVH amongst children on dialysis 6/11 
(54.4%) and children with CKD not requiring dialysis 7/35 (20%) (p=0.036).  
 
25. There is a significant correlation between the number of Anti-Hypertensive Medications 
taken and the percentage of children with LVH (p=< 0.001). 
     Children on 1 anti-HT had 6.3% chance of LVH, those on 2 anti-HT medications had           
      77.8% chance of LVH, those of 3 anti-HT medications had 42.9% chance of LVH and    
      100% of children using 4 anti-HT medications had LVH. 
26. There was a statistically significant difference between the LV Mass of those children 
with CKD not requiring Dialysis (88.7 gm) and those on Dialysis (142.6 gm p= 0.003).  
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27. There was a statistically significant difference between the LVMI of those children with 
CKD not requiring Dialysis (42.5 gm/m^2.7) and those on Dialysis (64 gm/m^2.7 p= 
0.026).  
28. There is a significant difference between the percentage of Fractional Shortening between 
children with CKD not requiring dialysis 32.99 %, and those on dialysis 27.35% 
(p=0.015).  
29. There was a statistically significant difference in the Ejection Fraction between children 
with CKD not requiring dialysis 62.3% and those on dialysis 53% (p= 0.017). 
30. There was no statistically significant difference in the E/A Velocity amongst children 
with CKD not requiring Dialysis 1.56, and those on dialysis 1.46 (p=0.696).  
31. The Systolic BP, Diastolic BP and Mean BP as measured by ABPM were found to 
correlate linearly with the LVMass (p=0.001).  
32. The Systolic BP, Diastolic BP and Mean BP as measured by ABPM were found to 
correlate linearly with the LVMass/ Ht (p=0.009, p= 0.004, p= 0.005 respectively).  
33. The Systolic BP, Diastolic BP and Mean BP as measured by ABPM were found to 
correlate linearly with the LVMass/ Ht^2.7 (p= 0.375, p=0.143 and p=0.214 
respectively).  
34. The Systolic BP and Diastolic BP as measured by Clinic Readings were found to 
correlate linearly with the LVMass (p=0.002, p= 0.012 respectively). 
35. There was no significant correlation between the stated duration of CKD and the LVMass 
(regression coefficient= -0.191, p=0.204). 
36. There was an apparent linear correlation between the Stated Duration of Hypertension 
and LVMass (regression coefficient=0.448, p=0.002). 
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37. In a Univariate analysis done to determine the indices which were the best predictors of LVH, BP 
Load and Clinic BP were the most significant (Odds ratio 12.7 and 8.9 respectively).  
 
 
  
 
CONCLUSIONS 
 
 
88 
 
CONCLUSIONS 
 
1. Children with CKD are at very high risk for cardiovascular morbidity (Hypertension and Left 
Ventricular Dysfunction). 
2. Masked Hypertension is common amongst children with CKD. As clinic BP recordings alone 
cannot detect masked hypertension; ABPM is a very useful tool. 
       3. LV Dysfunction is also common in children with CKD. 
       4. Clinic BP readings and BP Index (by ABPM) are significant predictors of LV Hypertrophy and 
important tools to monitor cardiovascular dysfunction. 
        5. L V Mass which correlates well with Systolic, Diastolic and Mean BP readings is an indicator of 
adequacy of BP control. 
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LIMITATIONS 
 
1. Normative values for Left Ventricular Mass or ABPM readings according to age, gender and 
height are not available for Indian children. Western standards used may not be representative of 
our population.  
2. Carotid Intimal Thickness could not be assessed as specific equipment was not available in our 
institution.  
3. Dyslipidemia which is an important risk factor for early atherosclerosis and cardiovascular risk 
was not assessed.  
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RECOMMENDATIONS 
 
1. All children with CKD should have an ABPM recording to detect hypertension and ECHO to 
detect cardiovascular risks at presentation and follow up thereafter.   
2. Strict BP control and early interventions to improve Left Ventricular Dysfunction should be 
undertaken to reduce morbidity and mortality.  
3. Our study design was a cross sectional study amongst children with CKD. More longitudinal 
studies are needed to determine cardiovascular risks with the progression of CKD. 
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ANNEXURE II 
 
CLINICAL RESEARCH FORM  
 
CARDIOVASCULAR MORBIDITY IN CHILDREN 
WITH CHRONIC RENAL DISEASE STUDY 
 
NAME:                                                              HOSPITAL NO.: 
AGE:                                                                  DATE OF BIRTH: 
GENDER:ADDRESS:       
PHONE NUMBER: 
 
HISTORY: 
 
CAUSE OF CRF (SPECIFY): 
1 Cystic disease 
2 Glomerular 
3 Tubular 
4 Dysplastic 
5 Uropathy 
 
DURATION OF CRF: 
 
CLASS OF CRF WITH GRF: 
 
DIALYSIS:  YES/NO 
 
DURATION OF DIALYSIS: 
 
HYPERTENSION: PRESENT (           )                           ABSENT (            ) 
                                DURATION: 
                                NUMBER OF ANTI HYPERTENSIVE DRUGS: 
                                WELL CONTROLLED: YES (         )            NO (        ) 
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CURRENT MEDICATIONS: 
 
ANTIHYPERTENSIVES: 
1 ACE Inhibitors 
2 Angiotensin Receptor Blockers 
3 Calcium Channel Blockers 
4 a Antagonists 
5 Others 
CALCIUM: 
CALCITRIOL: 
PHOSPHATE BINDERS: 
IRON: 
ERYTHROPOIETIN: 
STATINS: 
BICARBONATE: 
ROCALTROL: 
OTHERS: 
 
EXAMINATION: 
 
WEIGHT: 
 
HEIGHT: 
 
BODY MASS INDEX: 
 
BODY SURFACE AREA:  
 
ODEMA CLASSIFICATION: 
 
CLINICAL BP (3 READINGS): 
 
 
AMBULATORY BP MONITORING (24 HRS): 
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INVESTIGATIONS: 
 
HEMOGLOBIN: 
SODIUM: 
POTASSIUM: 
BICARBONATE: 
CALCIUM: 
PHOSPHORUS: 
CREATININE: 
UREA: 
PARATHYROID HORMONE 
LIPID PROFILE: 
Cholesterol: 
TAG: 
HDL: 
LDL: 
URINE ROUTINUE: 
PROTEINURIA: 
URINE PROTEIN/CREATININE RATIO: 
VITAMIN D LEVELS: 
TRANSFERRIN SATURATION/ TOTAL IRON BINDING CAPASITY: 
CALCIUM x PHOSPHATE PRODUCT: 
 
CAROTID INTIMAL THICKNESS BY USG DOPPLER: 
 
 
ECHO PARAMETERS: 
LV Mass: 
LVM Index: LVM 
                   Height 
Relative Wall Thickness: 
LV Hypertrophy:  Concentric 
                              Eccentric 
Normal LV Geometry: 
LV Diastolic action: 
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ANNEXURE III 
 
INFORMED CONSENT FORM 
 
PATIENT INFORMATION SHEET 
 
PEDIATRIC NEPHROLOGY UNIT  
CHRISTIAN MEDICAL COLLEGE AND HOSPITAL VELLORE 
 
Title of Research: To study the cardiovascular consequences in children with Chronic 
Kidney Disease 
 
You are being requested to allow your child to participate in a study to see if they have any 
increased cardiovascular risks due to Chronic Kidney Disease.  
 
What is the need for the study? 
Chronic Kidney Disease affects children world wide. These children have hypertension, heart 
failure and abnormal lipid profiles, all of which increase their cardiovascular risks. In children 
with CKD 40% of the deaths are due to cardiovascular causes. By checking Blood Pressure, 
Carotid USG Doppler, ECHO testing we hope to detect these cardiovascular risks amongst your 
children early, thereby preventing cardiac morbidity and mortality.  
 
Is there any harm to your child in participating in the study? 
We plan to do additional tests in all children: 
1 24 hours Ambulatory Blood Pressure Monitoring: This is a simple test which checks Blood 
Pressure over 24 hours. It does not cause any pain or discomfort to the child. 
2 ECHO: This is a painless, non invasive test which tells us about the functioning of the heart 
and early onset heart failure.  
3 USG Doppler of Carotid Intimal Thickness: This is a USG Doppler test of the neck veins to 
detect any atherosclerosis.  
All these tests are non-invasive tests and do not cause any pain or radiation exposure to your 
child. These tests are recommended in all children with CKD, but are not being done on a routine 
basis as yet.  
 
If your child takes part, what will be done? 
If you give consent for your child’s participation in the study we will enter the details about your 
child’s disease into a Performa. In addition to the routine blood tests, we will do three new tests.  
We will measure the 24 hours Ambulatory Blood Pressure, ECHO and USG Doppler of the 
Carotids to determine Intimal Thickness. All other treatments that your child is already receiving 
will be continued.  
 
Can your child withdraw from this study after it starts? 
Your child’s participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to allow your child’s participation at any time during the study. If you do 
so, this will not affect your usual treatment in the hospital in any way.  
 
100 
 
 
 
Will you have to pay for the study tests? 
The 24 hours Ambulatory Blood Pressure Monitoring, ECHO and USG Doppler of Carotids for 
Intimal thickness will be done free of cost. Any other treatment that your child usually takes will 
continue and the routine charges for the treatment will be paid by you.  
 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but your child will not be 
identified by name in any publication or presentation of results. However your child’s medical 
notes may be reviewed by the people associated with the study, without your additional 
permission, should you decide to allow your child to participate in the study. 
 
If you have any further questions, please contact Dr Dulari Gupta or Dr Indira Agarwal 
(Tel: 0416-2283348 or email dularigupta@gmail.com) 
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PATIENT CONSENT FORM 
 
 
Study Title: To study the cardiovascular consequences of Chronic Kidney Disease in 
children. 
 
Participant’s Name:    
 
Hospital Number: 
 
 
I ___________________________________________________________________                                                                
Father/ Mother/ Guardian of                              ________declare that:  
(please tick the boxes) 
 
I have read the Patient Information Sheet provided to me regarding the study and have clarified 
any doubts that I had. (          ) 
 
I also understand that my child’s participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting my child’s 
usual treatment or my legal rights. (         ) 
 
I understand that my child will not be charged for the tests done under the study but will have to 
pay for the tests done for standard care. (         ) 
 
I understand that the study staff and the institutional ethics committee members will not need my 
permission to look at my child’s records even if I withdraw from the study. I agree to this access. 
(         ) 
 
I understand that my child’s identity will not be revealed in any information released to third 
parties or publishers. (        ) 
 
I voluntarily agree to let my child take part in this study. (        ) 
 
 
Name:                                                                                 Name of Witness:  
 
Relation to participant:                                                     Relation to participant: 
 
Signature:                                                                           Signature: 
 
Date:                                                                                    Date:  
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ANNEXURE IV 
LEFT VENTRICULAR MASS TABLES 
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ANNEXURE V 
ABPM TABLES 
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ANNEXURE VI 
ABPM DATA SAMPLE 
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          ABSTRACT 
 
TITLE OF THE ABSTRACT           : A prospective cross-sectional study of the cardiovascular                
                                                             consequences in children with Chronic Kidney Disease 
DEPARTMENT                                 : Department of Paediatrics         
NAME OF THE CANDIDATE        : Dr Dulari Gupta 
DEGREE AND SUBJECT                : MD Paediatrics 
NAME OF THE GUIDE                   : Dr Indira Agarwal 
 
OBJECTIVES: Describe the objectives of your study (maximum 30 words) 
 
To study prevalence of cardiovascular risks amongst children with CKD by measuring Left Ventricular 
Dysfunction using ECHO and prevalence of Hypertension both manifest (clinic BP Readings) and 
masked (Ambulatory BP monitoring).  
 
METHODS: Explain the clinical and statistical methods used (maximum 100 words) 
 
Children, aged 1-18 years with Chronic Kidney Disease who presented to the Pediatric Nephrology OPD, 
General Pediatric OPD or Inpatient Facilities were recruited.   
Informed consent was taken from all parents. A detailed history and complete physical examination was 
done. Routine Blood tests (Hemoglobin, Sodium, Potassium, Creatinine, Urea, Calcium, Phosphorus, 
Alkaline Phosphatase, Bicarbonate, Parathyroid hormone levels) were noted.  The mean of 3 clinic BP 
readings was recorded. Ambulatory BP was performed over a 24 hour period using the Spacelabs 
Healthcare machine. ECHO was done to determine Left Ventricular Hypertrophy. Data was analyzed 
using SPSS software and chi square tests of significance.  
 
RESULTS:  Summarise the findings and conclusions of your study (maximum 90 words) 
 
Forty six children with CKD were studied (Male: Female 4.1:1). Obstructive uropathy was found 
to be the commonest cause of CKD. Forty two children had cardiovascular morbidity (93.1%). 
LVH was present in 28.26 % children. Clinic Hypertension was present in 21.7% .ABPM helped 
to detect latent hypertension in 32 additional children who had normal clinic BP.  
 
Left Ventricular Hypertrophy was found to linearly correlation with the ABPM and Clinic BP. 
Univariate analysis showed BP Index and Clinic BP to significantly contribute to LVH.  
 
We conclude that latent Hypertension is common amongst children with CKD. We recommend 
ABPM in every child with CKD to detect hypertension and monitor adequacy of hypertensive 
control.  
 
 
 
 
 
 
S no name id sex age height weight bsa bmi cause
dura- 
tion
gfr class
dia- 
lysis
Duration of 
Dialysis
HT
Duration of 
HT
HT 
control
no. of anti HT
1 surya 813056b 0 13 139 27.28 1.05 14.1 1 20 18.36 2 1 4 1 4 1 2
2 meghana 028448f 1 6 108 18 0.73 15.4 1 7 18.56 1 0 0 1 5 0 3
3 alok yadav 81506d 0 5 109 16.6 0.71 14 3 24 33.31 0 0 0 1 0 3
4 amar kumar das 105944f 0 13 165 40.3 1.4 14.8 4 48 32.02 0 0 0 1 1 0 1
5 tanvir sheam 678614d 0 15 148.8 31.8 1.17 14.5 1 144 49.6 0 0 0 1 22 1 2
6 kiranjit biswas 785907d 0 12 137 31.1 1.1 16.6 3 108 45.67 0 0 0 1 9 1 2
7 nazmus sakib 841588c 0 12 144 56.7 1.47 27.3 4 84 27.5 1 0 0 0 0 1 1
8 selv vinayagam 976429d 0 14 158 53.7 1.53 21.5 3 6 13.6 2 1 8 1 1 0 0
9 vignesh n 661380d 0 16 159.5 38.6 1.34 15.3 1 23 64.91 2 1 20 1 23 0 3
10 monisha 978513d 1 14 135.5 27.7 1.03 15.2 3 8 12.76 1 0 0 0 0 1 0
11 vishnu 310052d 0 5 109.6 15.8 0.7 13.3 3 41 6.26 2 1 0 1 13 0 2
12 shubham kumar 678186d 0 16 157 37.8 1.31 15.3 4 24 23.94 1 0 0 1 24 1 2
13 keshav ram sahu 030692f 0 9 117 19 0.79 13.9 3 7 7.31 2 1 3 1 3 0 4
14 premnath 979489b 0 11 145.7 41 1.28 19.5 4 126 26.49 1 0 0 1 24 1 2
15 prthibiraj barik 193478f 0 15 166 41.8 1.43 15.2 4 2 10.2 1 1 1 1 1 1 2
16 wahengbam dashibala 203196f 1 14 146 34.4 1.2 16.1 1 24 37.18 0 0 0 0 0 1 0
17 akhas dom 060141f 1 11 123 22.6 0.89 14.9 4 7 15.91 1 0 0 1 7 1 2
18 mohammed s 228209f 0 13 157 58.9 1.59 23.9 1 6 41.47 0 0 0 0 0 1 0
19 rozhan ali 047248c 0 11 108 16.78 0.71 14.3 4 132 37.43 0 0 0 1 3 1 1
20 raja v 539831d 0 12 113 18.56 0.76 14.5 3 33 22.86 2 1 30 0 0 1 0
21 rishi raghavendran 228705f 0 13 150 39.2 1.29 17.4 3 48 31.16 0 0 0 0 0 1 1
22 vijaya priya 608170d 1 14 153 35 1.25 15 3 3 38.42 0 0 0 0 0 1 1
23 anand s 134526c 0 11 134 25.5 0.99 14.2 4 132 8.69 2 1 3 1 4 1 3
24 bitan bera 239720f 0 11 131 23.6 0.94 13.8 3 7 21.48 2 1 3 1 3 0 4
25 parkavi 551548d 1 13 124.5 20.7 0.86 13.5 4 120 22.9 1 0 0 1 24 1 1
26 gangadhara 947648d 0 11 135 25.3 0.99 13.9 4 96 29.26 1 0 0 0 0 0 0
27 sudharson 896410d 0 13 156 45.2 1.41 18.6 4 154 50.79 0 0 0 1 0 0 3
28 debham saha 954703c 0 17 168 46 1.5 16.3 4 60 50.91 0 0 0 1 33 1 3
29 sudipta mondol 259172f 0 11 148 38 1.26 17.3 1 3 23.49 1 1 1 1 2 1 1
30 mohammed zaith 589689c 0 8 119 20.2 0.82 14.3 4 89 19.36 1 0 0 1 12 1 1
31 somojeet modak 260990f 0 9 134 22.8 0.95 12.7 4 114 36.85 0 0 0 0 0 0 1
32 roshan kumar 827840b 0 12 149 33 1.19 14.9 3 14 30.68 0 0 0 0 0 0 0
33 arvind 163511f 0 14 136 29 1.06 15.7 4 150 32.94 0 0 0 0 0 0 1
34 ravindran 152643c 0 11 129.2 23.86 0.94 14.3 3 132 30.9 0 0 0 0 0 1 1
35 furquanul haque 562142c 0 16 143.2 33.1 1.16 16.2 4 120 16.46 1 0 0 0 0 0 1
36 jatin sharma 220366f 0 7 107 13.8 0.65 12.1 0 3 29.72 1 0 0 0 0 0 0
37 soumitra manna 779138b 1 13 134.6 28.8 1.04 16 4 144 21.65 1 0 0 0 0 0 0
38 samuvel 045336c 0 12 126.2 23 0.91 14.5 3 132 29.45 1 0 0 1 48 1 1
39 Karthik 497918B 0 14 146 45.8 1.35 21.5 4 172 23.44 1 0 0 0 0 0 0
40 indumathy 852689d 1 6 110 15.5 0.7 12.8 4 41 32.35 0 0 0 0 0 0 1
41 niveda 132557d 1 14 138.2 30.8 1.1 16.2 3 36 26.26 1 0 0 0 0 0 1
42 adarsh 338748d 0 8 128 33 1.07 20.1 3 96 43.73 0 0 0 1 84 0 2
43 ramana 915292c 0 6 115.4 18 0.77 13.6 4 61 42.17 0 0 0 0 0 0 0
44 muniyappan 669607d 0 3 77 10.8 0.46 18.2 4 32 13.07 2 0 0 0 0 0 1
45 teja semha 450147d 0 7 105 17 0.7 15.4 3 24 25.9 1 0 0 0 0 0 0
46 Suditi dwivedi 379943d 1 13 137 27.4 1.04 14.6 4 24 7.61 2 1 10 1 8 0 3
THESIS DATA SHEET
S 
no
name id acei arb
Calcium 
Channel 
Blockers
Beta 
Block-
ers
ab
vaso- 
dilators
Ca
rocal-
trol
Iron
erythro-
poietin
Bicarbo-
nate
calcit-riol
clinic 
BP
clinic 
BP1
clinic 
BP2
1 surya 813056b 0 1 1 0 0 0 1 1 0 0 0 0 110 120 92
2 meghana 028448f 1 1 1 0 0 0 0 0 0 0 1 0 122 134 124
3 alok yadav 81506d 1 0 1 1 0 0 1 0 1 0 1 0 115 101 94
4 amar kumar das 105944f 0 0 0 1 0 0 0 1 0 1 1 0 120 120 150
5 tanvir sheam 678614d 1 0 1 0 0 0 1 0 1 0 0 0 132 133 109
6 kiranjit biswas 785907d 1 0 1 0 0 0 1 0 1 0 0 0 82 116 103
7 nazmus sakib 841588c 1 0 0 0 0 0 1 1 1 1 1 1 120 105 128
8 selv vinayagam 976429d 0 0 0 0 0 0 1 1 1 0 1 0 151 142 133
9 vignesh n 661380d 1 0 1 1 0 0 0 1 1 0 0 0 184 167 170
10 monisha 978513d 0 0 0 0 0 0 1 1 1 1 1 0 110 120 108
11 vishnu 310052d 1 0 1 0 0 0 1 0 1 1 1 0 148 147 151
12 shubham kumar 678186d 0 0 1 0 0 1 1 0 1 0 1 0 120 126 148
13 keshav ram sahu 030692f 1 0 1 0 1 1 1 1 1 0 1 0 132 132 148
14 premnath 979489b 1 0 1 0 0 0 0 0 1 0 0 0 104 124 120
15 prthibiraj barik 193478f 0 0 1 0 1 0 1 1 1 0 0 0 114 134 120
16 wahengbam dashibala 203196f 0 0 0 0 0 0 0 0 0 0 0 0 117 144 133
17 akhas dom 060141f 1 0 1 0 0 0 1 1 1 0 1 0 100 123 120
18 mohammed s 228209f 0 0 0 0 0 0 0 0 0 0 0 0 100 134 119
19 rozhan ali 047248c 1 0 0 0 0 0 1 1 1 0 1 0 107 97 96
20 raja v 539831d 0 0 0 0 0 0 1 1 1 1 1 0 115 113 119
21 rishi raghavendran 228705f 1 0 0 0 0 0 0 1 1 0 1 0 98 99 117
22 vijaya priya 608170d 1 0 0 0 0 0 0 1 1 0 0 1 99 120 120
23 anand s 134526c 1 0 1 0 1 0 1 0 1 1 1 0 89 104 124
24 bitan bera 239720f 0 1 1 0 1 1 1 1 1 1 0 0 140 139 126
25 parkavi 551548d 1 0 0 0 0 0 0 1 1 0 1 0 106 116 111
26 gangadhara 947648d 0 0 0 0 0 0 1 1 1 1 1 1 93 114 99
27 sudharson 896410d 0 1 1 0 1 0 1 1 1 1 1 0 113 137 129
28 debham saha 954703c 1 1 1 0 0 0 1 0 1 0 1 0 129 120 121
29 sudipta mondol 259172f 0 0 1 0 0 0 0 0 1 1 1 0 116 114 118
30 mohammed zaith 589689c 1 0 0 0 0 0 1 1 1 0 1 0 81 90 96
31 somojeet modak 260990f 1 0 0 0 0 0 1 0 1 0 1 1 102 100 94
32 roshan kumar 827840b 0 0 0 0 0 0 1 1 1 1 1 0 108 126 119
33 arvind 163511f 1 0 0 0 0 0 1 1 1 0 1 0 100 110 95
34 ravindran 152643c 0 1 0 0 0 0 1 1 1 0 1 0 94 90 98
35 furquanul haque 562142c 1 0 0 0 0 0 1 1 1 1 1 0 88 88 104
36 jatin sharma 220366f 0 0 0 0 0 0 1 1 1 1 0 1 86 96 97
37 soumitra manna 779138b 0 0 0 0 0 0 1 1 1 0 1 0 109 117 113
38 samuvel 045336c 1 0 0 0 0 0 1 0 1 0 1 0 92 100 90
39 Karthik 497918B 0 0 0 0 0 0 1 1 1 0 1 0 97 90 90
40 indumathy 852689d 1 0 0 0 0 0 1 0 1 0 1 0 78 74 106
41 niveda 132557d 1 0 0 0 0 0 1 1 1 0 0 0 90 90 124
42 adarsh 338748d 0 0 1 1 0 0 1 0 1 0 1 0 114 104 114
43 ramana 915292c 0 0 0 0 0 0 1 0 1 0 1 0 110 99 92
44 muniyappan 669607d 1 0 0 0 0 0 1 1 0 0 0 1 80 82 100
45 teja semha 450147d 0 0 0 0 0 0 1 1 1 0 1 0 98 98 94
46 Suditi dwivedi 379943d 0 1 1 1 0 0 1 1 1 1 1 0 113 130 120
THESIS DATA SHEET
S no name id
clinic 
BP3
clinic 
BP4
clinic 
BP5
avg SBP avgDBP
Clinic 
BP
hb so-dium
potas-
sium
bicar-
bonat
calcium
phos-
phorus
creat urea pth upuc CaPO4 lvidd
1 surya 813056b 60 70 58 107.3333333 62.666667 A 8 136 5.5 17 9.3 3.6 5.3 59 609.9 33.48 4.9
2 meghana 028448f 89 84 94 126.6666667 89 P 8.4 138 4.1 23 7.3 3.5 3.2 105 12 8.79 25.55 4.1
3 alok yadav 81506d 59 50 47 103.3333333 52 A 11.7 141 7.2 20 9.6 4.6 1.8 79.6 0.17 44.16 3.3
4 amar kumar das 105944f 89 90 100 130 93 P 12 135 5.1 19 9.5 3.5 3.6 32 457.9 33.25 4.8
5 tanvir sheam 678614d 106 84 81 124.6666667 90.333333 P 13 135 4.8 20 10.1 4.5 2.1 171.7 2.04 45.45 3.8
6 kiranjit biswas 785907d 42 56 70 100.3333333 56 A 10.4 128 5.5 22 9.7 4.7 2.1 148 149.5 4.84 45.59 4.3
7 nazmus sakib 841588c 80 72 78 117.6666667 76.666667 A 11.9 136 4.4 21 8.5 4.2 2.8 100 201.5 7.2 35.7 3.6
8 selv vinayagam 976429d 99 84 83 142 88.666667 P 10.5 129 4 19 8.5 5.7 8.13 168 867.8 48.45 3.9
9 vignesh n 661380d 129 110 116 173.6666667 118.33333 P 11.7 135 4.5 23 9.1 4.6 1.72 35 290.8 41.86 4.2
10 monisha 978513d 60 70 57 112.6666667 62.333333 A 7.2 141 5.6 17 8.3 3.5 5.84 146 630.2 29.05 3.9
11 vishnu 310052d 122 122 115 148.6666667 119.66667 P 7 133 4.6 27 9.9 5.1 9.63 127 170.7 50.49 3.7
12 shubham kumar 678186d 67 85 86 131.3333333 79.333333 A 11 138 3.9 22 8.8 4.3 4.59 64 229 37.84 3.9
13 keshav ram sahu 030692f 92 98 98 137.3333333 96 P 10.2 137 5.4 20 8.7 11.2 159 891.7 0 4.7
14 premnath 979489b 61 90 86 116 79 A 9.6 132 4.5 18 7.6 4 3.85 83 2.5 30.4 4.2
15 prthibiraj barik 193478f 70 78 67 122.6666667 71.666667 A 7 137 5.5 14 8.8 5.7 11.39 114 3.67 50.16 4.8
16 wahengbam dashibala 203196f 87 101 83 131.3333333 90.333333 P 11.6 138 4.2 21 8.8 4.6 2.16 29 177.9 3.96 40.48 3.6
17 akhas dom 060141f 70 93 80 114.3333333 81 A 8.1 135 6.2 21 9.6 5.5 5.41 128 178.2 52.8 2.4
18 mohammed s 228209f 60 65 55 117.6666667 60 A 10.7 137 4.7 38 8.3 4 2.65 29 57.4 0.13 33.2 3.6
19 rozhan ali 047248c 59 56 61 100 58.666667 A 8.1 135 7.1 12 8.8 2.9 2.02 87 537.8 25.52 3.5
20 raja v 539831d 78 75 80 115.6666667 77.666667 A 11.5 142 4.8 16 10 6.1 3.46 53 955.4 61 3.9
21 rishi raghavendran 228705f 75 63 86 104.6666667 74.666667 A 8.9 138 3.5 20 8.4 2.6 3.37 39 1327 21.84 3.4
22 vijaya priya 608170d 67 86 70 113 74.333333 A 8.9 135 4 19 9 3.3 2.19 259.4 29.7 3.5
23 anand s 134526c 41 51 90 105.6666667 60.666667 A 9.9 134 6 22 9.2 5.5 8.98 154 59.1 50.6 3.6
24 bitan bera 239720f 114 99 78 135 97 P 9.4 140 3.6 19 8.9 5 4.27 41 261.7 44.5 4.3
25 parkavi 551548d 72 90 68 111 76.666667 A 11.4 134 5.3 16 9.3 5 2.99 79 200 4.42 46.5 3.7
26 gangadhara 947648d 52 70 70 102 64 A 11.7 135 5.4 19 7.9 3.2 3.23 771.5 2.25 25.28 3.5
27 sudharson 896410d 55 68 90 126.3333333 71 P 11.7 142 4.8 19 8.4 4.7 2.15 29 99.9 0.74 39.48 4.3
28 debham saha 954703c 61 80 64 123.3333333 68.333333 A 12.7 134 4.8 15 9 3.5 2.31 91.5 1.46 31.5 2.9
29 sudipta mondol 259172f 74 52 68 116 64.666667 A 9.7 132 3.3 15 8.2 5.9 4.41 90 29 0.01 48.38 4.3
30 mohammed zaith 589689c 43 50 53 89 48.666667 A 10.6 133 4.9 20 9.1 5.7 3.38 87 85.6 0.97 51.87 3
31 somojeet modak 260990f 77 65 65 98.66666667 69 A 10 129 4.4 18 8.2 3.7 2 67 45 30.34 4.2
32 roshan kumar 827840b 69 80 71 117.6666667 73.333333 A 10.3 136 4.6 18 9.3 6.4 3.4 63 5 1.54 59.52 4
33 arvind 163511f 50 78 54 101.6666667 60.666667 A 10.7 141 4 18 8.2 2.7 2.89 51 466.6 22.14 3.6
34 ravindran 152643c 60 40 50 94 50 A 8.5 139 4.7 21 8.9 5.9 2.3 56 180.3 1.18 52.51 3.9
35 furquanul haque 562142c 41 42 63 93.33333333 48.666667 A 10.1 134 5 12 7.7 5.4 6.09 137 913.1 1.2 41.58 3.5
36 jatin sharma 220366f 52 63 59 93 58 A 7.1 137 3.3 12 7.3 2.3 1.98 75 1713 2.21 16.79 3.1
37 soumitra manna 779138b 67 65 74 113 68.666667 A 11 139 4.2 16 9.1 3.8 3.42 106 114.5 2.49 34.58 3.1
38 samuvel 045336c 46 70 60 94 58.666667 A 9.2 138 4.7 22 8.6 4.5 3 81.9 38.7 3.4
39 Karthik 497918B 48 60 60 92.33333333 56 A 12.6 138 4 18 8.4 4.8 4.36 74 386.3 40.32 3.9
40 indumathy 852689d 48 36 65 86 49.666667 A 9.5 133 4.2 26 1.87 79 164.3 0 2.8
41 niveda 132557d 50 50 74 101.3333333 58 A 6.9 138 5.6 19 8.6 5.5 2.89 440 47.3 4
42 adarsh 338748d 73 79 60 110.6666667 70.666667 A 14.1 141 3.5 18 9 4.2 1.61 41 137.3 0.31 37.8 3.8
43 ramana 915292c 70 67 60 100.3333333 65.666667 A 12.3 139 4.3 14 9.2 6.4 1.5 41.8 58.88 3.3
44 muniyappan 669607d 50 64 70 87.33333333 61.333333 A 9.2 136 6 19 9.5 3.9 3.24 267 2.74 37.05 2.9
45 teja semha 450147d 60 43 58 96.66666667 53.666667 A 12.3 136 3.2 18 8.4 3.7 2.23 151 2.52 31.08 3.4
46 Suditi dwivedi 379943d 63 74 68 121 68.333333 A 8.2 135 6.2 21 6.7 6.5 9.9 226 1900 15.12 43.55 5.3
THESIS DATA SHEET
S 
no
name id lvids lvpwd rvdd ivsd fs ef e a lvmht
ABPM 
sbp
ABPM 
sbp1
ABPM 
sbp2
ABPM 
dbp
ABPM 
dbp1
ABPM 
dbp2
ABPM 
mbp
ABPM 
mbp1
ABPM 
mbp2
1 surya 813056b 3.9 1.2 0.89 0.98 20.9 42.4 1.4235151 122 123 117 80 80 77 92 92 89
2 meghana 028448f 2.7 0.68 1.2 0.91 34 63.4 0.89267385 113 114 107 71 72 68 86 87 84
3 alok yadav 81506d 2.2 0.7 0.73 0.73 31.3 60.4 0.53785167 116 119 108 67 72 54 85 88 75
4 amar kumar das 105944f 3.2 0.91 1.9 0.83 33.1 61.6 0.8557558 118 121 102 82 84 68 95 98 81
5 tanvir sheam 678614d 2.7 0.9 1 0.9 28.9 56.4 0.67835355 108 108 106 71 73 63 84 84 79
6 kiranjit biswas 785907d 2.9 0.84 0.92 0.95 32.7 61.5 0.892344 101 103 88 64 67 50 78 80 66
7 nazmus sakib 841588c 2.6 0.82 1.9 0.79 27.3 54 92.8 68.6 0.55086306 102 103 99 65 66 63 77 78 74
8 selv vinayagam 976429d 2.7 1 1.4 1.1 31.3 59.9 0.82809235 140 142 126 96 99 78 109 111 92
9 vignesh n 661380d 2.9 0.92 0.77 1.1 29.9 57.5 0.8718044 124 125 124 88 88 85 100 101 99
10 monisha 978513d 2.6 0.84 0.81 0.95 33.7 63.1 0.77046228 117 118 112 71 73 64 87 88 82
11 vishnu 310052d 2.6 1 0.98 1.5 29.6 57.5 1.42906569 104 105 99 68 69 65 80 81 75
12 shubham kumar 678186d 2.7 1.1 1 0.98 29.5 57.2 145 94.1 0.82195832 127 129 114 76 79 59 94 97 80
13 keshav ram sahu 030692f 4.1 1.1 1.3 1 12.8 27.5 150.5 71.1 1.50176656 123 123 122 89 88 95 100 100 104
14 premnath 979489b 2.5 0.98 1.1 0.87 39.1 70 0.84475723 135 135 139 86 86 86 99 100 99
15 prthibiraj barik 193478f 3.3 1.3 1.5 1.2 30 57.2 1.39837108 127 127 125 68 69 60 87 88 82
16 wahengbam dashibala 203196f 2.5 0.87 0.83 0.76 31.5 60.4 97.7 69.1 0.55263372 134 136 120 86 89 73 100 103 87
17 akhas dom 060141f 1.5 1.4 1.4 1.4 38 70.7 0.86149828 100 100 98 58 58 58 73 74 72
18 mohammed s 228209f 2.5 0.8 1 1 30.6 59 94.3 64.7 0.59026915 127 128 120 63 64 60 85 86 82
19 rozhan ali 047248c 2.4 0.7 1.1 0.8 31.4 60.4 0.63711111 96 96 98 58 58 55 71 72 69
20 raja v 539831d 2.7 0.61 0.65 0.45 31.7 60.4 101 71.8 0.46593369 137 137 138 86 86 86 104 104 104
21 rishi raghavendran 228705f 2.3 1 1.2 1 31.2 60.1 108 83.4 0.65859413 105 106 99 68 70 58 81 82 74
22 vijaya priya 608170d 2.3 0.79 0.98 0.87 32.8 62.3 0.51709082 110 111 105 72 73 65 85 86 78
23 anand s 134526c 2.5 0.92 0.77 0.65 30.7 59.3 0.57190274 116 116 110 76 77 71 89 90 83
24 bitan bera 239720f 3.4 1.1 1 0.9 20.9 42.9 50.8 49.9 1.0867884 134 137 124 96 98 86 108 109 98
25 parkavi 551548d 2.6 0.53 1.1 0.61 30.2 58.3 0.42304244 99 102 90 65 68 56 79 82 69
26 gangadhara 947648d 2.4 0.83 1.3 0.6 31.4 60.4 0.4777842 117 118 110 77 78 66 90 91 83
27 sudharson 896410d 3 0.77 1.4 0.92 29.8 57.2 0.72528918 118 120 109 74 76 64 89 90 81
28 debham saha 954703c 2 1.1 0.72 0.98 33.3 63.7 117 90.3 0.49372225 121 121 121 73 74 65 90 90 86
29 sudipta mondol 259172f 2.9 1.1 0.9 32.6 61.2 77.5 58.7 0.34672995 121 121 121 74 74 75 89 89 89
30 mohammed zaith 589689c 1.9 0.54 1.1 0.69 36.7 68.1 91.4 55.5 0.34443325 91 92 88 55 55 54 68 69 66
31 somojeet modak 260990f 2.9 0.5 0.5 0.5 31 59 90.3 75.5 0.41660179 92 94 83 60 61 51 72 73 62
32 roshan kumar 827840b 2.8 0.79 1.2 0.87 30.5 58.5 0.65833211 124 126 112 73 75 64 90 91 83
33 arvind 163511f 2 0.76 1.2 0.79 44.8 77 112.5 73.1 0.55371924 118 120 110 59 61 49 79 80 75
34 ravindran 152643c 2.7 0.76 1.3 0.61 31.3 59.9 0.56424737 108 110 98 62 63 59 78 79 74
35 furquanul haque 562142c 2.3 0.91 1.9 1.1 32.8 62.3 0.72617607 101 101 102 60 60 55 75 75 73
36 jatin sharma 220366f 2 0.6 0.9 0.8 35.5 66.4 97.7 57.8 0.48140082 110 112 99 79 81 71 90 91 82
37 soumitra manna 779138b 2.1 0.88 1.2 0.74 29.7 58.4 104.6 69.6 0.46940606 119 122 107 71 74 57 85 74 72
38 samuvel 045336c 2.3 0.7 1.2 0.8 34 64 0.52030935 106 106 102 71 72 62 83 84 79
39 Karthik 497918B 2.6 0.8 0.9 0.8 33.3 62.7 114 64.2 0.61336022 98 98 97 63 63 61 76 76 73
40 indumathy 852689d 1.9 0.79 1.1 0.89 32.7 63.1 0.51841402 91 94 83 54 56 48 68 70 61
41 niveda 132557d 2.4 0.7 0.9 0.6 40 71.2 91.8 54.8 0.51445488 110 111 103 69 70 66 83 84 77
42 adarsh 338748d 2.6 1 1.3 2.7 32.2 61.1 117 52.3 2.3892695 133 133 132 87 88 82 102 103 97
43 ramana 915292c 2.3 0.6 0.8 0.6 30.3 58.9 98.7 73.1 0.40204867 119 123 109 79 81 71 92 94 85
44 muniyappan 669607d 1.8 0.78 1.3 0.46 38 69.9 98.5 47.9 0.50942028 93 95 88 54 57 46 69 70 64
45 teja semha 450147d 2.3 0.72 0.68 0.91 32.1 61.4 96.7 59.2 0.70154597 95 96 91 57 58 51 69 70 65
46 Suditi dwivedi 379943d 3.7 1 1.1 1.1 30.5 57.5 1.56029711 133 134 128 86 86 85 99 100 98
THESIS DATA SHEET
S no name id BP Load LVH LV Mass NDS NDD
SBP 
Index
DBP 
Index
1 surya 813056b 60.37 P 197.869 4.87805 3.75 1.0066 1.038
2 meghana 028448f 18.82 P 96.4088 6.14035 5.55556 0.97 0.958
3 alok yadav 81506d 57.69 P 58.6258 9.2437 25 0.996 0.9
4 amar kumar das 105944f 66.66 P 141.2 15.7025 19.0476 0.912 1.058
5 tanvir sheam 678614d 27.27 P 100.939 1.85185 13.6986 0.87 0.92
6 kiranjit biswas 785907d 7.27 P 122.251 14.5631 25.3731 0.841 0.832
7 nazmus sakib 841588c 10.81 A 79.3243 3.8835 4.54545 0.832 0.843
8 selv vinayagam 976429d 96.42 A 130.839 11.2676 21.2121 1.098 1.241
9 vignesh n 661380d 75 A 139.053 0.8 3.40909 0.973 1.138
10 monisha 978513d 40.74 A 104.398 5.08475 12.3288 0.994 0.958
11 vishnu 310052d 19.44 P 156.626 5.71429 5.7971 0.893 0.913
12 shubham kumar 678186d 53.57 A 129.047 11.6279 25.3165 1.01 0.984
13 keshav ram sahu 030692f 90.27 P 175.707 0.81301 -7.9545 1.053 1.16
14 premnath 979489b 84.74 P 123.081 -2.963 0 1.102 1.115
15 prthibiraj barik 193478f 34.48 P 232.13 1.5748 13.0435 0.982 0.877
16 wahengbam dashibala 203196f 89.28 A 80.6845 11.7647 17.9775 1.12 1.142
17 akhas dom 060141f 4.65 A 105.964 2 0 0.848 0.755
18 mohammed s 228209f 34.42 A 92.6723 6.25 6.25 1.01 0.816
19 rozhan ali 047248c 0 A 68.808 -2.0833 5.17241 0.77 0.766
20 raja v 539831d 93.33 A 52.6505 -0.7299 0 1.077 1.133
21 rishi raghavendran 228705f 10.63 A 98.7891 6.60377 17.1429 0.846 0.881
22 vijaya priya 608170d 24.63 A 79.1149 5.40541 10.9589 0.897 0.947
23 anand s 134526c 35.08 A 76.635 5.17241 7.79221 0.966 0.988
24 bitan bera 239720f 97.91 P 142.369 9.48905 12.2449 1.126 1.248
25 parkavi 551548d 4.34 A 52.6688 11.7647 17.6471 0.856 0.892
26 gangadhara 947648d 46.29 A 64.5009 6.77966 15.3846 0.975 1.001
27 sudharson 896410d 17.2 A 113.145 9.16667 15.7895 0.938 0.958
28 debham saha 954703c 14.1 A 82.9453 0 12.1622 0.922 0.946
29 sudipta mondol 259172f 13.58 A 51.316 0 -1.3514 0.975 0.959
30 mohammed zaith 589689c 0 A 40.9876 4.34783 1.81818 0.779 0.717
31 somojeet modak 260990f 0 A 55.8246 11.7021 16.3934 0.766 0.78
32 roshan kumar 827840b 28.57 A 98.0915 11.1111 14.6667 1 0.946
33 arvind 163511f 17.72 A 75.3058 8.33333 19.6721 0.983 0.767
34 ravindran 152643c 5.12 A 72.9008 10.9091 6.34921 0.908 0.806
35 furquanul haque 562142c 0 A 103.988 -0.9901 8.33333 0.824 0.778
36 jatin sharma 220366f 34.28 A 51.5099 11.6071 12.3457 0.925 1.051
37 soumitra manna 779138b 37.68 A 63.1821 12.2951 22.973 1.011 0.958
38 samuvel 045336c 17.14 A 65.663 3.77358 13.8889 0.899 0.924
39 Karthik 497918B 2.12 A 89.5506 1.02041 3.1746 0.8 0.817
40 indumathy 852689d 3.84 A 57.0255 11.7021 14.2857 0.781 0.728
41 niveda 132557d 24.07 A 71.0977 7.20721 5.71429 0.926 0.923
42 adarsh 338748d 75.75 P 305.826 0.75188 6.81818 1.118 1.131
43 ramana 915292c 68 A 46.3964 11.3821 12.3457 1.011 1.056
44 muniyappan 669607d 6.6 A 39.2254 7.36842 19.2982 0.798 0.725
45 teja semha 450147d 0 A 73.6623 5.20833 12.069 0.798 0.758
46 Suditi dwivedi 379943d 100 P 213.761 4.47761 1.16279 1.129 1.16
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